

# **TRIPTOLIDE ANALOGS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS**

## **FIELD OF THE INVENTION**

5 The present invention is in the area of pharmaceutical chemistry and specifically relates to novel compounds and pharmaceutical compositions for the treatment of autoimmune and inflammatory disorders. This application claims priority to U.S.S.N. 60/237,557, filed on October 2, 2000.

## **BACKGROUND OF THE INVENTION**

10 Autoimmune and inflammatory diseases affect more than fifty million Americans. The immune system functions as the body's major defense against diseases caused by invading organisms. This complex system fights disease by killing invaders such as bacteria, viruses, parasites or cancerous cells while leaving the body's normal tissues unharmed. The immune system's ability to distinguish the body's normal tissues, or self, from foreign or cancerous tissue, or non-self, is an essential feature of normal immune system function. A second essential feature is memory, the ability to remember a particular foreign invader and to mount an enhanced defensive response when the previously encountered invader returns. The loss of recognition of a particular tissue as self and the subsequent immune response directed against that tissue produce serious illness.

20 Inflammation is involved in a large number of physiological and pathological conditions affecting animals and humans. Inflammatory responses can usually be traced to an immune response to an antigen, allergen, irritant, endotoxin or to tissue damage. The process is complex, involving a large number of components, many of which display pleiotropic effects, many of which are amplifiers or inhibitors of other components. While many instances of an inflammatory response are well-controlled and self-limited, many pathologic conditions arise from uncontrolled or inappropriate responses, resulting in both acute and chronic conditions.

25

As a result of basic research in molecular and cellular immunology over the last ten to fifteen years, approaches to diagnosing, treating and preventing these immunological based diseases have been changed forever. By dissecting the individual components of the immune system, those cells, receptors and mediators that are critical to the initiation and progression of immune responses have been, and continue to be, elucidated. Crystallographic analysis of proteins encoded in the major histocompatibility complex, identification of an antigen-specific T cell receptor, and development of a basic understanding of the complex cytokine network have all contributed to a revolution in immunology. Various immunosuppressive agents have proved to be useful in the prevention of transplantation rejection and in the treatment of autoimmune diseases such as rheumatoid arthritis, nephritis, uveitis, thyroiditis, and early stage of insulin dependent diabetes mellitus, systemic lupus erythematosus, psoriasis and inflammatory bowel disease.

The immune system when operating normally is involved in precise functions such as recognition and memory of, specific response to, and clearance of, foreign substances (chemical and cellular antigens) that either penetrate the protective body barriers of skin and mucosal surfaces (transplanted tissue and microorganisms such as bacteria, viruses, parasites) or arise de novo (malignant transformation). The arsenal of the immune response is composed of two major types of lymphocytes that are either B-lymphocytes (B cells, responsible for producing antibodies which attack the invading microorganisms) or the T-lymphocytes (T cells, responsible for eliminating the infected or abnormal target cells) in cooperation with macrophages. The cascade of principal events in the immune system is more fully described by I. Roitt, J. Brostoff and D. Male in "Immunology", 3rd edition, Mosby, 1993 which is herein incorporated by reference, and may be summarized as follows.

The response is initiated by the interaction of an antigen with macrophages and surface antibodies on B cells. The macrophages ingest and process the antigen. The activated macrophages secrete interleukin-1 (IL-1) and tumor necrosis factor (TNF), and display the processed antigen on the cell surface together with a major antihistocompatibility antigen. Both IL-1 and TNF initiate a number of processes involving inflammation. Also, IL-1 induces proliferation of B cells and synthesis of antibodies. But more importantly, IL-1 activates T cells that release a series of lymphokines including interleukin-2 (IL-2) that activate the proliferation of T cells and

cytotoxic lymphocytes. In autoimmune diseases, the system is unable to distinguish between "non-self" antigen and "self" antigen and will start to produce autoantibodies or autoreactive T cells that attack the normal components of the body.

Inflammatory reactions differ not only as to the nature of the triggering event, but also in the types of cells mediating the response and in the biochemical nature of the end effectors. In particular, inflammation mediated by monocyte/macrophage activity can result in severe chronic or fatal conditions, including immune complex-initiated primary inflammatory disorders such as glomerulonephritis, chronic interstitial nephritis, interstitial pneumonitis, Crohn's disease, ulcerative colitis, osteoarthritis, biliary cirrhosis and the like, affecting other organ systems; also including connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematosus and the like; further including secondary progressive inflammatory diseases in which the central cause of tissue destruction is uncontrolled inflammatory/fibrotic processes regardless of the nature of the initiating insult, for example chronic hepatitis, whether the initial insult be infectious, toxic, alcohol, etc., radiation induced chronic inflammations of lung, kidney, central nervous system, inflammations induced by crystal deposition, such as gout, and various forms of post-traumatic inflammatory injury, such as arthritis. Many prior therapeutic strategies have been directed at alleviating the various symptoms of the diseases, without affecting the process itself.

Leukocyte activation leads to the release of degradative enzymes, the generation of reactive oxygen species and the biosynthesis of locally acting pro-inflammatory autacoids. Among the latter, oxygenated metabolites of arachidonic acid are recognized major products of leukocyte activation and exert potent biological effects on cellular functions. The arachidonate lipoxygenase (LO) family of enzymes catalyze the formation of highly potent biologic mediators in leukocytes and platelets. The predominant LO pathway in polymorphonuclear leukocytes (PMN) and macrophages is 5-LO, leading to the formation of leukotrienes (LTs) and 5-hydroxyeicosatetraenoic acid (5-HETE) (Samuelson, B. et al. (1987) Science 237:1171-1176). The sulfidopeptide LTs (LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>) and the non-peptidyl LTB<sub>4</sub>, elicit potent biological responses: LTC<sub>4</sub> and LTD<sub>4</sub> contract vascular, pulmonary, and gastrointestinal smooth muscle, and increase vascular permeability to macromolecules (Lewis, R. A. et al. (1984) J. Clin. Invest. 73:889-897; Samuelson, B. et al. (1987) supra). LTB<sub>4</sub> has minimal spasmogenic properties. Its primary target appears to be (PMN)s, which express specific high and low affinity receptors for LTB<sub>4</sub>. Through

the former, LTB<sup>4</sup> is the most potent chemotactic substance yet described for this cell and also increases PMN aggregation and adhesion to endothelium. Through the latter, it acts as a calcium ionophore, leading to PMN activation, stimulation of phosphoinositide turnover, release of lysosomal enzymes and an increase in oxidative metabolism. In turn, activated PMNs are the best studied source of LTB<sub>4</sub> where its synthesis is coupled to activation of protein kinase C.

Direct effects of LTC<sub>4</sub>, LTD<sub>4</sub> and LTB<sub>4</sub> on normal and inflamed glomerulus have been measured. LTA<sub>4</sub> is a product of 5-LO activity and serves as a precursor for both LTC<sub>4</sub> and LTB<sub>4</sub>. The former requires the activity of a glutathione-S-transferase while the latter is the product of LTA<sub>4</sub> hydrolase. LTD<sub>4</sub> is the product of a .gamma.-glutamyl transferase removing a glutamyl moiety from LTC<sub>4</sub>. LTD<sub>4</sub> has a powerful effect of reducing glomerular capillary ultrafiltration coefficient acting on both normal and inflamed glomeruli. It is believed to be a major mediator of functional deterioration in glomerulonephritis. LTC<sub>4</sub> has been shown to reduce renal blood flow and glomerular filtration rate acting on normal kidney and is considered to act similarly in inflamed glomerulus. By contrast, LTB<sub>4</sub> has little direct effect on normal glomerulus. However it is a powerful chemotactic agent for PMNs. The role of LTB<sub>4</sub> in glomerulonephritis is seen as an indirect amplifier of leukocyte-dependent reductions in glomerular perfusion due to enhancement of PMN recruitment and activation.

An alternative metabolic pathway initiated by 15-lipoxygenase (15-LO) activity leads to compounds having antagonistic effects to the products of 5-LO activity. Hydroperoxidation of arachidonic acid by 15-LO leads to the formation of 15-S-hydroxyeicosatetraenoic acid (15-S-HETE). Dual lipoxygenation at both the 5 and 15 positions in activated neutrophils and macrophages yields a class of "lipoxygenase interaction products" (Samuelson, B. et al. (1987), supra). Like 5-LO, 15-LO gene expression is restricted largely to leukocyte cell lines, but has also been detected in reticulocytes and airway epithelial cells. Using cDNA probes for human 15-LO, gene expression in glomerular cell lines has not been detected by northern analysis. Macrophages are a particularly rich source of 15-LO and hence of 15-S-HETE and LXs. Three biologically active lipoxins have been identified. LXA<sub>4</sub>, (5S,6R,15S)-5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid, LXB<sub>4</sub> (5S,14R,15S)-5,14,15-trihydroxy-6,10,12-trans-8-cis-eicosatetraenoic acid, and 7-cis-11-trans-LXA<sub>4</sub> (Samuelson, B. et al. (1987), supra; Nicolau, K. C. et al. (1989) *Biochem. Biophys. Acta* 1003:44-53;



the pharmacological profile of their renal actions has been characterized recently (Katoh, T. et al. (1992) *Am. J. Physiol.* 263:F436-442). Lipoxin synthesis, like that of leukotrienes, can also occur via transformation of leukocyte-generated LTA<sub>4</sub> by either 15-LO or 12-LO in adjoining cells, such as mesangial cells or platelets.

5 Evidence for a generalized anti-inflammatory role for 15-LO products has been derived from clinical observations and experimental studies in vivo and in vitro. Administration of 15-S-HETE causes regression of psoriatic lesions in humans and significantly reduces the clinical severity of a canine arthritis model.

10 The compound, 15-S-HETE, is a specific antagonist of LTB<sub>4</sub> -induced chemotaxis of PMNs. Other chemotactically-active substances are not inhibited. 15-S-HETE also aborts leukocyte activation, abrogates adhesion of PMNs to endothelium and depresses LTB<sub>4</sub> synthesis by leukocytes. During experimental glomerulonephritis, production of LTB<sub>4</sub> reaches a peak about three hours after injury and declines to baseline levels after about 72 hours. In contrast, 15-S-HETE levels increase gradually over time up to two weeks, reaching levels consistent with the amounts required to achieve the antagonistic effects just described. The kinetics are consistent with the view that a slower-acting 15-LO pathway functions to inhibit and limit the intensity and scope of an inflammatory process, once the process has been initiated. The lipoxins, especially LXA<sub>4</sub>, also have significant anti-inflammatory functions. For example, LXA<sub>4</sub> acts as an antagonist of the leukotrienes, having anti-chemotactic effect, and having direct vasorelaxation activity and augmentation of glomerular filtration rates. LXA<sub>4</sub> acts as a competitive inhibitor of LTD<sub>4</sub> receptor binding. LXA<sub>4</sub> also prevents or inhibits PMN adhesion to mesangial cells.

20 The manifold response modalities of the immune systems of mammals are regulated by a variety of secreted immunoregulatory proteins termed cytokines. These include various colony stimulating factors, chemokines, interleukins and interferon-γ (IFN-γ). The characteristics of a variety of immune-type responses is largely controlled by the cell types involved and the cytokine network associated therewith in each case. For example, the involvement of the Th1 subset of helper T-cells leads to secretion of IFN-γ and interleukin-2 (IL-2) which appear to promote a delayed-type hypersensitivity response. Another type of response, mediated by Th2 subset of helper T cells, is characterized by secretion of IL-4 and IL-5, which act to promote antibody responses (Mosmann, T. R. et al. (1989) *Annu. Rev. Immunol.* 7: 145-173). There is a complex

series of positive or negative responses to each set of cytokines by many cell types in the immune system. Much has been learned concerning the function of cytokine networks. However new findings and newly discovered cytokines often require those skilled in the art to revise their theories of cytokine network interactions.

5           The system of experimentally induced glomerulonephritis in the rat has yielded significant information as to the processes of disease development and the nature of the biochemical mediators of tissue destruction. See Badr, K. (1992) *Kidney International* 42(Suppl. 38): S-101-S-108, incorporated herein by reference. The presence of immune complexes in the glomerulus, regardless of their sources, routes of formation, or intraglomerular localization, inevitably and necessarily provokes a complement-mediated  
10           influx and activation of polymorphonuclear leukocytes (PMN). The very transient nature of the PMN infiltrate (first few hours following immune activation) renders it an infrequent finding in renal biopsies from patients with various forms of glomerulonephritis, leading to under-appreciation of the potential role of this early inflammatory event in the eventual outcome of disease. PMNs are, however, detected  
15           frequently when biopsies are performed during ongoing acute injury such as in patients with post-infectious glomerulonephritides. Characteristically, this initial wave of neutrophil infiltration/activation is replaced by monocyte infiltration and macrophage proliferation and activation. During this secondary ("autologous") phase, it is postulated  
20           that injury might be perpetuated not only by the consequences of activation/proliferation of macrophages and indigenous glomerular cells (particularly mesangial and epithelial cells), but also by fresh immune reactions to neo-antigens from host tissue exposed as a result of proteolytic and lipid peroxidative consequences of initial leukocyte activation and degranulation. The number of participating cells in the more chronic phase of immune  
25           injury, the interactions among these "stimulated" cell populations, and, consequently, the myriad of peptide and lipid-derived mediators which underlie cellular injury and the eventual replacement of normal glomerular architecture by extracellular matrix (fibrosis), is staggering. While strategies aimed at arresting glomerular injury by targeting the mediators of matrix expansion and scar formation show promise, the complexity of the  
30           "mediator soup" during this phase of injury and the various cell populations involved (including tubulointerstitial elements) present serious theoretical and practical obstacles to the development of effective therapeutic interventions.

Targeting the mechanisms which govern the severity of early immune-mediated injury rests on the premise that those diseases which most commonly lead to renal failure due to immune deposition are, for the most part, progressive over months to years, suggesting incremental phases of nephron loss. Evidence from pathologic examinations in several forms of glomerulonephritis indicates that injury is heterogeneous: the number of affected versus healthy glomeruli varies among patients, as well as over time in individual patients. Moreover, within individual glomeruli, lesions are often segmental with inflammatory reactions present in certain lobules, while others are totally normal. These data, as well as a clinical course characterized by steadily diminishing renal reserve over highly varying periods of time, suggest strongly that, in an individual patient, "early" injury is occurring continuously in some fixed proportion of nephrons. It is therefore reasonable to predict that institution of therapy which specifically targets those early events will arrest initial injury in those nephrons, albeit small in number, in which it is underway and, more importantly, prevent or abort its development in intact nephrons, despite the potential continued deposition or formation of immune complexes in these normal glomeruli. This latter assumption is based on the dramatic evidence from experimental studies indicating that mere deposition of antigen-antibody complexes in the glomerular capillary wall or mesangium, in the absence of cellular infiltration (as in leukocyte- or complement-depleted animals) or the capacity to generate arachidonate metabolites (as in fatty acid deficient animals), is without any detrimental acute or chronic consequences to glomerular structure and functions.

Each element in the cascade of the immune response may be considered as a potential site for pharmacological intervention. For example, adrenocorticosteroids act in the first stages of the immune response, interact with the macrophages and, inhibit the synthesis and release of IL-1. Other immunosuppressive agents used in the treatment of autoimmune diseases have been identified, such as azathioprine and methotrexate for rheumatoid arthritis, cyclophosphamide for nephritic conditions of immune origin, and cyclosporin for rheumatoid arthritis, uveitis, early onset insulin dependent diabetes mellitus, psoriasis, nephritic syndrome and aplastic anemia.

In addition, immunosuppressive agents have proved to be useful in preventing and treating organ transplantation rejection that may occur in allograft transplantation. In allograft transplantation one person donates an organ to a genetically disparate individual while in xenograft transplantation an organ of one species is transplanted into a member of

another species. In those cases, the use of cyclosporin has shown a real improvement in the condition of the person receiving the organ. However, the therapeutic index of the available immunosuppressive drugs is narrow, none of the drugs are completely effective and their use has been limited by severe toxicity.

5 Autoimmune disease results from the immune system attacking the body's own organs or tissues, producing a clinical condition associated with the destruction of that tissue. An autoimmune attack directed against the joint lining tissue results in rheumatoid arthritis; an attack against the conducting fibers of the nervous system results in multiple sclerosis. The autoimmune diseases most likely share a common pathogenesis and the need for safe and effective therapy.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2

as cyclosporin A, which specifically inhibits T cell activation, and specific antibodies directed against T lymphocytes or surface receptors that mediate their activation (Briggs J. D., Immunology Letters Jul. 29(1-2):89-94 (1991). All of these drug therapies are limited in effectiveness, in part because the doses needed for effective treatment of transplant rejection may increase the patient's susceptibility to infection by a variety of opportunistic invaders, and in part because of direct toxicity and other side effects. For example, cyclosporin A, currently the most commonly used agent, is significantly toxic to the kidney. This nephrotoxicity limits the quantity of drug that can be safely given.


Many useful pharmaceutical agents are derived from plants. In some cases, the plant-derived compound provides a drug lead that is then chemically modified to improve its pharmacological activity and/or simplify its structure for chemical synthesis. In many cases, e.g., where the plant-derived compound is a complex structure, chemical synthesis is impractical, and the compound must be obtained by direct extraction from plants. If the plant is in short supply, or a complex purification scheme is required, or the yield is low, direct extraction from plants may not be practical.

Production of pharmaceutical agents using plant cell cultures has been reported for only a few cases. In general, obtaining what are usually complex compounds by this approach has not been feasible to date.

One plant that illustrates the potential for plant secondary metabolites as useful pharmaceutical agents, and also the difficulty of producing the plant products in practical yields, is *Tripterygium wilfordii* (TW). A number of compounds having immuno-suppressive or other activities have been isolated from extracts of root tissues from TW, including tripterinin (PCT Application PCT/US94/02540), 16-hydroxytriptolide (Ma, 1991a; 1992a), triptiolide (Ma, 1991b), celastrol (Zhang, 1986a,b), triphchlorolide (Zhang, 1992), triptophenolide (Deng, 1992), triptonide (Wu, 1992), tripterine (Zhang, 1990a), tripterygic acid (Zhang, 1990b), sesquiterpene alkaloids (Ya, 1990), isowilfordine (Ya, 1991), sesquiterpene esters (Takaishi, 1990; 1991a; 1992a), sesquiterpene polyol esters (Takaishi, 1991b,c), phenanthrene derivatives (Takaishi, 1991d) tripterygone (Zhang, 1991), salaspermic acid (Chen, 1992), other diterpene lactone epoxide compounds (Zheng, 1991; Ma, 1992b), and diterpene quinones (Shen, 1992; Takaishi, 1992b; Shishido, 1993).

It has now been discovered that various extracts from the poisonous plant *Tripterygium wilfordii* play an important part in autoimmune and inflammatory

suppression, in particular, triptolide. Triptolide contains an unusual triepoxide moiety and an  $\alpha,\beta$  unsaturated  $\gamma$ -lactone in the diterpene skeleton, and it has potent antileukemic and immunosuppressive activities.



**Triptolide**


However, in most cases, these compounds are structurally complex molecules which are difficult to purify in useful quantities from plants, and difficult or impossible to synthesize in practical yields. The activity from the crude compounds found in *T. wilfordii* shows activity, however after purification the activity decreases. The isolated compounds have also been shown to decompose over time and the process is quite slow. At present, it is not known whether cultured cells from *T. wilfordii* could be induced to produce any of these compounds in commercially useful amounts.

It would therefore be desirable to provide immunosuppressive compounds by methods that overcome the limitations noted above. Additionally, it is further desired to provide immunosuppressive compounds having improved water solubility and low toxicity. At the same time it would be advantageous to discover additional plant-derived compounds, or mimics thereof, with therapeutically useful properties. In addition, it would be desirable for such compounds to exhibit immunosuppressive activity in their water soluble form, or to be convertible to an immunosuppressive form by metabolic processes in vivo or in vitro.


#### SUMMARY OF THE INVENTION

The present invention provides novel compounds, pharmaceutical compositions and methods for the treatment or prophylaxis of autoimmune or inflammatory disorders. These compounds may act by inducing 15-lipoxygenase (15-LO) in the treatment of such disorders.


In particular, compounds are provided of the formula (I)-(XX):




(I)




(II)




(III)




(IV)




(V)




(VI)




(VII)




(VIII)




(IX)




(X)




(XI)




(XII)




(XIII)




(XIV)




(XV)




(XVI)




(XVII)



(XVIII)



(XIX)



(XX)

and their pharmaceutically acceptable salts and/or prodrugs, thereof, wherein:

each dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

each A, B, D, E and M is independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;

each G is independently  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$  or  $\text{SR}^{11}$ ;

5 each  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

20 In a preferred embodiment, the compound exhibits an  $\text{EC}_{50}$  of less than 25, 15, 10, 5 or 1 micromolar.

In another further embodiment of the present invention is to provide a novel and efficient method for the synthesis of the compounds.

25 In yet another embodiment of the invention, the compounds of the present invention are administered optionally in a pharmaceutically acceptable carrier or diluent.

30 In yet another embodiment, the active compound can be administered in combination or alternation with another immunosuppressant or anti-inflammatory agent. In combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion



rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

In yet another embodiment of the invention, compositions comprising the compounds of the present invention, optionally in a pharmaceutically acceptable carrier or diluent, in combination with another immunosuppressant or anti-inflammatory agent are provided.

In yet another embodiment, a method for the treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided, comprising administering an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent.

In yet another embodiment, a method for the treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided, comprising administering a pharmaceutical composition comprising an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, in combination with one or more other immunosuppressant or anti-inflammatory agent.

In yet another embodiment, a use of an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent for the simultaneous, separate or sequential treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided.

In yet another embodiment, a use of an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent in the manufacture of a medicament for the simultaneous, separate or sequential treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided.

## BRIEF DESCRIPTION OF THE FIGURES

**Figure 1** is a nonlimiting example of the general synthesis for the intermediates of triptolide derivatives.

**Figure 2** is a nonlimiting example of the general stereospecific synthesis for triptolide derivatives from intermediates.

**Figure 3** illustrates one embodiment of the synthesis of triptolide derivatives according to the present invention.

**Figure 4** is a nonlimiting example of general methodologies that can be used to obtain different epoxides of the present invention.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel compounds, pharmaceutical compositions and methods for the treatment autoimmune and inflammatory disorders. In particular, the present invention relates to novel triptolide derivatives and compositions for the inducement of 15-lipoxygenase (15-LO) in the treatment of autoimmune and anti-inflammatory disorders.

In a preferred embodiment, the compound exhibits an  $EC_{50}$  of less than 25, 15, 10, 5 or 1 micromolar.

In another further embodiment of the present invention is to provide a novel and efficient method for the synthesis to the compounds previously mentioned.

In yet another embodiment of the invention, the compounds of the present invention are administered optionally in a pharmaceutically acceptable carrier or diluent.

In yet another embodiment, the active compound can be administered in combination or alternation with another immunosuppressant or anti-inflammatory agent. In combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to

be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

5           In yet another embodiment of the invention, compositions comprising the compounds of the present invention, optionally in a pharmaceutically acceptable carrier or diluent, in combination with another immunosuppressant or anti-inflammatory agent are provided.

10           In yet another embodiment, a method for the treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided, comprising administering an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent.


15           In yet another embodiment, a method for the treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided, comprising administering a pharmaceutical composition comprising an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, in combination with one or more other immunosuppressant or anti-inflammatory agent.

20           In yet another embodiment, a use of an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent for the simultaneous, separate or sequential treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided.

25           In yet another embodiment, a use of an effective amount of an active compound of the present invention, optionally in a pharmaceutically acceptable carrier, optionally in combination or alternation with one or more other immunosuppressant or anti-inflammatory agent in the manufacture of a medicament for the simultaneous, separate or sequential treatment or prophylaxis of autoimmune or inflammatory disease in a host is provided.

## I. Compounds of the Present Invention

In one embodiment of the present invention, a structure of the formula (I) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A and B are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (II) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A, B and D are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (III) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:


A, B, D and E are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (IV) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A, B and E are independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;

5  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$  and  $\text{R}^{10}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

20 In another embodiment of the present invention a structure of the formula (V) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

B, D and E are independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;


25 G is  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$  or  $\text{SR}^{11}$ ;

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $XR^9$  (wherein  $X = O, S$  or  $NR^{10}$ );

alternatively, one or more of  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$ , or  $R^5$  and  $R^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (VI) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

$B$  is  $O, S, NR^7$  or  $CR^7R^8$ ;

$G$  is  $OR^{11}, NR^{11}R^{12}$  or  $SR^{11}$ ;

$R^1, R^2, R^3, R^4, R^5$  and  $R^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine,




hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (VII) is provided:



(VII)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A and B are independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$ , or  $R^5$  and  $R^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (VIII) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

B and E are independently O, S,  $NR^7$  or  $CR^7R^8$ ;

G is  $OR^{11}$ ,  $NR^{11}R^{12}$  or  $SR^{11}$ ;


$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $XR^9$  (wherein  $X = O, S$  or  $NR^{10}$ );

alternatively, one or more of  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$ , or  $R^5$  and  $R^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered

ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (IX) is provided:



(IX)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

E is O, S,  $NR^7$  or  $CR^7R^8$ ;

G is  $OR^{11}$ ,  $NR^{11}R^{12}$  or  $SR^{11}$ ;


$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $XR^9$  (wherein  $X = O, S$  or  $NR^{10}$ );

alternatively, one or more of  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$ , or  $R^5$  and  $R^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

5

In another embodiment of the present invention a structure of the formula (X) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A is O, S,  $NR^7$  or  $CR^7R^8$ ;

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $XR^9$  (wherein  $X = O, S$  or  $NR^{10}$ );

alternatively, one or more of  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$ , or  $R^5$  and  $R^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XI) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A and E are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XII) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A, D and E are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XIII) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A and D are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XIV) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

B is O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;

G is  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$  or  $\text{SR}^{11}$ ;


$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.



In another embodiment of the present invention a structure of the formula (XV) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

B and D are independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;


G is  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$  or  $\text{SR}^{11}$ ;

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XVI) is provided:



(XVI)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

D is O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;


G is OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup> or SR<sup>11</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XVII) is provided:



(XVII)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

D and E are independently O, S,  $\text{NR}^7$  or  $\text{CR}^7\text{R}^8$ ;


G is  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$  or  $\text{SR}^{11}$ ;

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or  $\text{XR}^9$  (wherein  $\text{X} = \text{O}, \text{S}$  or  $\text{NR}^{10}$ );

alternatively, one or more of  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$ , or  $\text{R}^5$  and  $\text{R}^6$ , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  and  $\text{R}^{12}$  is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XVIII) is provided:



(XVIII)

or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


G is OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup> or SR<sup>11</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XIX) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;


A, B and M are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In another embodiment of the present invention a structure of the formula (XX) is provided:



or its pharmaceutically acceptable salt or prodrug thereof, wherein:

The dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;

B and M are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

G is OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup> or SR<sup>11</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR<sup>9</sup> (wherein X = O, S or NR<sup>10</sup>);

alternatively, one or more of R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup>, or R<sup>5</sup> and R<sup>6</sup>, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

each R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate.

In a sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A and B are independently O, S, NR<sup>7</sup> or CR<sup>7</sup>R<sup>8</sup>;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = O$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = NR<sup>10</sup>.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = CR<sup>8</sup>R<sup>9</sup>.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,



a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{S}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = S$ ,  $B = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = S$ ,  $B = NR^8$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{S}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = S$ ,  $B = S$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9$ ;  $B = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ;


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (I) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,


a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}, \text{NR}^{14}$  or  $\text{S}$ );


$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}, \text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In a particular embodiment of the present invention, the compounds of the formula (I) are the following species:


 <p style="text-align: center;">(I)</p>							
A	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	Me	H	H	H	Me	Me
O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	Ph	H	H	H	Me	Me
O	O	Me	Me	H	H	Me	Me
O	O	<i>i</i> -Pr	Me	H	H	Me	Me



(I)

A	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	Ph	Me	H	H	Me	Me
O	O	Me	H	Me	H	Me	Me
O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	Ph	H	Me	H	Me	Me
O	O	Me	H	H	Me	Me	Me
O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	Ph	H	H	Me	Me	Me
O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me



 <p style="text-align: center;">(I)</p>							
A	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5           A = O, B = O, D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

10           R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>18</sup> (X = O, NR<sup>19</sup> or S);

15

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = NR<sup>10</sup>, D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>18</sup> (X = O, NR<sup>19</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = CR<sup>8</sup>R<sup>9</sup>, D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>18</sup> (X = O, NR<sup>19</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = S, D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{O}$ ,  $\text{D} = \text{O}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = CR<sup>8</sup>R<sup>9</sup>, B = CR<sup>18</sup>R<sup>19</sup>, and D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>18</sup> (X = O, NR<sup>19</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>, and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = CR<sup>8</sup>R<sup>9</sup>, B = CR<sup>18</sup>R<sup>19</sup>, and D = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{S}$ , and  $\text{D} = \text{O}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{18}$  ( $X = O, NR^{19}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ ,  $\text{D} = \text{CR}^{18}\text{R}^{19}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );


20  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

25  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ; and

30 the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.



In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{18}$  ( $X = O, NR^{19}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ; and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ , and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{D} = \text{CR}^{18}\text{R}^{19}$ ;


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{19}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ , and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}$  and  $R^{21}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{18}$  ( $X = O, NR^{19}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ , and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (II) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );


$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}$  and  $R^{21}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,


sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{18}$  ( $\text{X} = \text{O}, \text{NR}^{19}$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ , and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.


In a particular embodiment of the present invention, the compounds of the formula (II) are the following species:

<div style="text-align: center;">  <p>(II)</p> </div>								
A	B	D	$\text{R}^1$	$\text{R}^2$	$\text{R}^3$	$\text{R}^4$	$\text{R}^5$	$\text{R}^6$
O	O	O	Me	H	H	H	Me	Me
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	O	Ph	H	H	H	Me	Me
O	O	O	Me	Me	H	H	Me	Me
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	O	Ph	Me	H	H	Me	Me
O	O	O	Me	H	Me	H	Me	Me
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me



(II)

A	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	O	Ph	H	Me	H	Me	Me
O	O	O	Me	H	H	Me	Me	Me
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	O	Ph	H	H	Me	Me	Me
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me



(II)

A	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = O$ ,  $E = O$  and  $D = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ ).

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$  and  $R^{17}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = NR^{20}$ ,  $E = O$ ,  $D = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ ).

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$  and  $R^{20}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$  and  $\text{R}^{20}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).



$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = O, E = S, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = NR^{10}, E = S, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = CR^8R^9, E = S, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = S, E = S, D = O.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup> and R<sup>22</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>.

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = O, E = CR<sup>8</sup>R<sup>9</sup>, D = O.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup> and R<sup>22</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{CR}^8\text{R}^9$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$  and  $\text{R}^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{CR}^{21}\text{R}^{22}$ ,  $\text{E} = \text{CR}^8\text{R}^9$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = S, E = CR^8R^9, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$  and  $R^{22}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = NR^{10}, E = NR^{23}, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = CR^8R^9, E = NR^{10}, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = S, E = NR<sup>10</sup>, D = O.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>.

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A = O, B = O, E = NR<sup>10</sup>, D = O.

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ ,  $\text{E} = \text{NR}^{10}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).



$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = NR^{10}, E = O, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = CR^{20}R^{21}, E = O, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$A = CR^8R^9, B = S, E = O, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = O, E = CR^{20}R^{21}, D = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = NR^{10}, E = CR^{20}R^{21}, D = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$A = CR^8R^9, B = CR^{20}R^{21}, E = CR^{22}R^{23}, D = O.$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .



In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .



In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide,

phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}, \text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{NR}^{24}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}, \text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}, \text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{CR}^{20}\text{R}^{21}$ ,  $\text{E} = \text{NR}^{10}$ ,  $\text{D} = \text{O}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}, \text{NR}^{14}$  or  $\text{S}$ ).



$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = S, E = NR^{10}, D = O$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = O, E = O, D = CR^8R^9$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$A = O, B = NR^{10}, E = O, D = CR^8R^9$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{S}$ ,  $\text{D} = \text{CR}^8\text{R}^9$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{S}$ ,  $\text{D} = \text{CR}^8\text{R}^9$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = CR^8R^9, E = S, D = CR^{20}R^{21}$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = S, E = S, D = CR^8R^9$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$A = O, B = O, E = CR^8R^9, D = CR^{20}R^{21}$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{CR}^8\text{R}^9$ ,  $\text{D} = \text{CR}^{20}\text{R}^{21}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{NR}^{10}$ ,  $\text{D} = \text{CR}^8\text{R}^9$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).



$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = NR^{10}, E = NR^{23}, D = CR^8R^9$ .

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).


$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

$A = O, B = CR^7R^8$ .

$E = NR^7, D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

$\text{A} = \text{CR}^7\text{R}^8$ ;  $\text{B} = \text{O}$ .

$\text{E} = \text{O}$ ,  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{CR}^{20}\text{R}^{21}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{CR}^{20}\text{R}^{21}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{CR}^{20}\text{R}^{21}$ ,  $\text{E} = \text{O}$ ,  $\text{D} = \text{CR}^{24}\text{R}^{25}$ .

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{S}$ ,  $\text{D} = \text{CR}^{21}\text{R}^{22}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{CR}^{20}\text{R}^{21}$ ,  $\text{E} = \text{S}$ ,  $\text{D} = \text{CR}^{24}\text{R}^{25}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = S, E = S, D = CR^{20}R^{21};$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = O, E = CR^{20}R^{21}, D = CR^{24}R^{25};$

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9, B = NR^{10}, E = CR^{21}R^{22}, D = CR^{24}R^{25};$


$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .



In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}, \text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{NR}^{10}$ ,  $\text{D} = \text{CR}^{21}\text{R}^{22}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}, \text{NR}^{14}$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}, \text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{NR}^{23}$ ,  $\text{D} = \text{CR}^{21}\text{R}^{22}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}, \text{NR}^{14}$  or  $\text{S}$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ ).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .

In another sub-embodiment, a structure of the formula (III) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:





$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ .


In a particular embodiment of the present invention, the compounds of the formula (III) are the following species:

 <p style="text-align: right;">(III)</p>								
B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	O	Me	H	H	H	Me	Me
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	O	Ph	H	H	H	Me	Me
O	O	O	Me	Me	H	H	Me	Me
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me




(III)

B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	O	Ph	Me	H	H	Me	Me
O	O	O	Me	H	Me	H	Me	Me
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	O	Ph	H	Me	H	Me	Me
O	O	O	Me	H	H	Me	Me	Me
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	O	Ph	H	H	Me	Me	Me
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	Me	H	H	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	H	H	Me	Me
CH <sub>2</sub>	O	O	Ph	H	H	H	Me	Me
CH <sub>2</sub>	O	O	Me	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	Me	H	Me	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
CH <sub>2</sub>	O	O	Ph	H	Me	H	Me	Me



(III)

B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
CH <sub>2</sub>	O	O	Me	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	Ph	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me



(III)

B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A is O, S or NR<sup>7</sup>;

5 B and E are independently selected from CR<sup>8</sup>R<sup>9</sup>, O, S or NR<sup>10</sup>;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

10 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

15 R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

20 and

the dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25 A = O, B = O, E = O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);



$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = NR^{10}, E = O$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl,

alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{S}$ ;


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide,

phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{S}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ;  $\text{B} = \text{O}$ ,  $\text{E} = \text{CR}^8\text{R}^9$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}, CR^{15}R^{16}CR^{17}R^{18}, CR^{15}=CR^{16}, CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O, B = NR^{10}, E = CR^7R^8$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = CR^8R^9$ ,  $E = CR^{21}R^{22}$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = S$ ,  $E = CR^8R^9$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ;  $\text{B} = \text{O}$ ,  $\text{E} = \text{NR}^{10}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = NR^{10}$ ,  $E = NR^{23}$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ,  $B = CR^8R^9$ ,  $E = NR^{10}$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{O}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{NR}^{10}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = O$ ;  $B = O$ ,  $E = O$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphoryl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9$ ;  $B = O$ ,  $E = O$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{O}$ ;


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{S}$ ;


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{S}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );


$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^8\text{R}^9$ ,  $\text{B} = \text{CR}^{21}\text{R}^{22}$ ,  $\text{E} = \text{CR}^{24}\text{R}^{25}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9$ ,  $B = S$ ,  $E = CR^{21}R^{22}$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$A = CR^8R^9$ ;  $B = O$ ,  $E = NR^{10}$ ;

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{A} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{NR}^{23}$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:




$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O, NR^{14}$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O, NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (IV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,


a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );


$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.


In a particular embodiment of the present invention, the compounds of the formula (IV) are the following species:

 <div style="text-align: right;">(IV)</div>								
A	B	D	$\text{R}^1$	$\text{R}^2$	$\text{R}^3$	$\text{R}^4$	$\text{R}^5$	$\text{R}^6$
O	O	O	Me	H	H	H	Me	Me
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	O	Ph	H	H	H	Me	Me
O	O	O	Me	Me	H	H	Me	Me
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me



(IV)

A	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	O	Ph	Me	H	H	Me	Me
O	O	O	Me	H	Me	H	Me	Me
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	O	Ph	H	Me	H	Me	Me
O	O	O	Me	H	H	Me	Me	Me
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	O	Ph	H	H	Me	Me	Me
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me

 <div style="text-align: right;">(IV)</div>								
A	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = O$ ,  $E = O$ , and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = NR^8$ ,  $E = O$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ ,  $\text{E} = \text{O}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = S, E = O and D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = O, E = S, D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{S}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = CR<sup>8</sup>R<sup>9</sup>, E = S, D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = S, E = S, D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{CR}^8\text{R}^9$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = NR^{10}$ ,  $E = CR^8R^9$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = CR^8R^9$ ,  $E = CR^{21}R^{22}$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{CR}^8\text{R}^9$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = NR^{10}$ ,  $E = NR^{23}$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = CR^8R^9$ ,  $E = NR^{10}$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{NR}^{10}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ;  $B = O$ ,  $E = NR^{10}$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = CR^8R^9$ ,  $E = NR^{10}$  and  $D = O$ ..

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ;  $\text{B} = \text{O}$ ,  $\text{E} = \text{O}$  and  $\text{D} = \text{CR}^8\text{R}^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = NR^{10}$ ,  $E = O$  and  $D = CR^8R^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = CR^8R^9$ ,  $E = O$ ,  $D = CR^{21}R^{22}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{O}$ , and  $\text{D} = \text{CR}^8\text{R}^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = O$ ,  $E = S$  and  $D = CR^8R^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = NR^{10}$ ,  $E = S$ ,  $D = CR^8R^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{CR}^8\text{R}^9$ ,  $\text{E} = \text{S}$ , and  $\text{D} = \text{CR}^{21}\text{R}^{22}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = S$ ,  $E = S$  and  $D = CR^8R^9$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ;  $B = O$ ,  $E = CR^8R^9$  and  $D = CR^{21}R^{22}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{CR}^9\text{R}^8$  and  $\text{D} = \text{CR}^{21}\text{R}^{22}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = CR^9R^8$ ,  $E = CR^{21}R^{22}$  and  $D = CR^{25}R^{24}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = OR^{26}$ ,  $B = S$ ,  $E = CR^9R^8$  and  $D = CR^{21}R^{22}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ;  $\text{B} = \text{O}$ ,  $\text{E} = \text{NR}^{10}$  and  $\text{D} = \text{CR}^9\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = NR<sup>10</sup>, E = NR<sup>23</sup> and D = CR<sup>9</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = OR<sup>26</sup>, B = CR<sup>9</sup>R<sup>8</sup>, E = NR<sup>10</sup> and D = CR<sup>21</sup>R<sup>22</sup>.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{OR}^{26}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{NR}^{10}$  and  $\text{D} = \text{CR}^9\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{28}R^{29}$ ,  $B = O$ ,  $E = O$ ,  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{27}R^{28}$ ,  $B = NR^{10}$ ,  $E = O$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^{27}\text{R}^{28}$ ,  $\text{B} = \text{CR}^9\text{R}^8$ ,  $\text{E} = \text{O}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{27}R^{28}$ ,  $B = S$ ,  $E = O$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{27}R^{28}$ ,  $B = O$ ,  $E = S$ ,  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^{27}\text{R}^{28}$ ,  $\text{B} = \text{NR}^{10}$ ,  $\text{E} = \text{S}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>27</sup>R<sup>28</sup>, B = CR<sup>9</sup>R<sup>8</sup>, E = S and D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>27</sup>R<sup>28</sup>, B = S, E = S and D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^{27}\text{R}^{28}$ ;  $\text{B} = \text{O}$ ,  $\text{E} = \text{CR}^9\text{R}^8$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{27}R^{28}$ ,  $B = NR^{10}$ ,  $E = CR^9R^8$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^{27}R^{28}$ ,  $B = CR^9R^8$ ,  $E = CR^{21}R^{22}$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^{27}\text{R}^{28}$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{CR}^9\text{R}^8$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>27</sup>R<sup>28</sup>, B = O, E = NR<sup>10</sup> and D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>27</sup>R<sup>28</sup>, B = NR<sup>10</sup>, E = NR<sup>23</sup> and D = O.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^{27}\text{R}^{28}$ ,  $\text{B} = \text{CR}^9\text{R}^8$ ,  $\text{E} = \text{NR}^{10}$  and  $\text{D} = \text{O}$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = S$ ,  $E = NR^7$  and  $D = O$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = O$ ,  $E = O$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^8$ ,  $\text{E} = \text{O}$ , and  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = CR^7R^8$ ,  $E = O$ , and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = S$ ,  $E = O$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^7\text{R}^8$ ,  $\text{B} = \text{O}$ ,  $\text{E} = \text{S}$  and  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = NR^8$ ,  $E = S$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = CR^7R^8$ ,  $E = S$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^7\text{R}^8$ ,  $\text{B} = \text{S}$ ,  $\text{E} = \text{S}$  and  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = O$ ,  $E = CR^7R^8$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = NR^8$ ,  $E = CR^7R^8$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^7\text{R}^8$ ,  $\text{B} = \text{CR}^7\text{R}^8$ ,  $\text{E} = \text{CR}^7\text{R}^8$  and  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );



R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>7</sup>R<sup>8</sup>, B = S, E = CR<sup>7</sup>R<sup>8</sup> and D = CR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

G = NR<sup>7</sup>R<sup>8</sup>, B = O, E = NR<sup>7</sup> and D = CR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$\text{G} = \text{NR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^8$ ,  $\text{E} = \text{NR}^7$  and  $\text{D} = \text{CR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = CR^7R^8$ ,  $E = NR^7$  and  $D = CR^7R^8$ .

In another sub-embodiment, a structure of the formula (V) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{13}$  ( $X = O$ ,  $NR^{14}$  or  $S$ );


$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^{11}$  ( $X = O$ ,  $NR^{12}$  or  $S$ );


$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^{13}R^{14}$  groups, connected by a tether, independently selected from  $CR^{15}R^{16}$ ,  $CR^{15}R^{16}CR^{17}R^{18}$ ,  $CR^{15}=CR^{16}$ ,  $CR^{15}R^{16}O$  or  $CR^{15}R^{16}NR^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

$G = NR^7R^8$ ,  $B = S$ ,  $E = NR^7$  and  $D = CR^7R^8$ .


In a particular embodiment of the present invention, the compounds of the formula (V) are the following species:

 (V)								
B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	O	Me	H	H	H	Me	Me
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	O	Ph	H	H	H	Me	Me
O	O	O	Me	Me	H	H	Me	Me
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	O	Ph	Me	H	H	Me	Me
O	O	O	Me	H	Me	H	Me	Me
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	O	Ph	H	Me	H	Me	Me
O	O	O	Me	H	H	Me	Me	Me
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	O	Ph	H	H	Me	Me	Me
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	Me	H	H	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	H	H	Me	Me




(V)

B	D	E	R <sup>I</sup>	R <sup>4</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
CH <sub>2</sub>	O	O	Ph	H	H	H	Me	Me
CH <sub>2</sub>	O	O	Me	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	O	O	Me	H	Me	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
CH <sub>2</sub>	O	O	Ph	H	Me	H	Me	Me
CH <sub>2</sub>	O	O	Me	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	Ph	H	H	Me	Me	Me
CH <sub>2</sub>	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me



(V)

B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me

 <p style="text-align: center;">(V)</p>								
B	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
CH <sub>2</sub>	O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>.

The dotted line indicates the presence of either a single or double bond;

B is selected from the groups that include CR<sup>7</sup>R<sup>8</sup>, O, S or NR<sup>7</sup>;

G is selected from the groups that include OR<sup>7</sup>, NR<sup>7</sup>R<sup>8</sup> or SR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>; and

The dotted line indicates the presence of either a single or double bond;

B is O;

G is OR<sup>7</sup>.



In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

The dotted line indicates the presence of either a single or double bond;

B is O;

G is  $NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

The dotted line indicates the presence of either a single or double bond;

B is O;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

The dotted line indicates the presence of either a single or double bond;

B is  $\text{CR}^7\text{R}^8$ ;

G OR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}_7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

The dotted line indicates the presence of either a single or double bond;

B is  $\text{CR}^7\text{R}^8$ ;

G is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is  $\text{CR}^7\text{R}^8$ ;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond;

B is S;

G is  $OR^7$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is S;

G is  $NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is S;

G is  $SR^7$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is  $\text{NR}^7$ ;

G is  $\text{OR}^7$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

20  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

25

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

30 The dotted line indicates the presence of either a single or double bond;

B is  $\text{NR}^7$ ;

G is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (VI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;


The dotted line indicates the presence of either a single or double bond;


B is  $\text{NR}^7$ ;

G is  $\text{SR}^7$ .



In a particular embodiment of the present invention, the compounds of the formula (VI) are the following species:

<div style="text-align: center;">  <p>(VI)</p> </div>							
G	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	Me	H	H	H	Me	Me
OH	O	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	Ph	H	H	H	Me	Me
OH	O	Me	Me	H	H	Me	Me
OH	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	Ph	Me	H	H	Me	Me
OH	O	Me	H	Me	H	Me	Me
OH	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	Ph	H	Me	H	Me	Me
OH	O	Me	H	H	Me	Me	Me
OH	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	Ph	H	H	Me	Me	Me
OH	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me

 (VI)							
G	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
OH	CH <sub>2</sub>	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

- 5 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

The dotted line indicates the presence of either a single or double bond;

$\text{B}$  is selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{A}$  is selected from the groups that include  $\text{O}$ ,  $\text{NR}^7$  or  $\text{S}$ .

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected

independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

The dotted line indicates the presence of either a single or double bond;

B is O;

A is O.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ .

The dotted line indicates the presence of either a single or double bond;

B is O;

A is  $NR^7$ .

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

5 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

10 R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>; and

15 The dotted line indicates the presence of either a single or double bond;

20 B is O;

A is S.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

30 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ .

The dotted line indicates the presence of either a single or double bond;

5 B is  $CR^7R^8$ ;

A is O.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

10  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

15  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

20  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

The dotted line indicates the presence of either a single or double bond;

25 B is  $CR^7R^8$ ;

A is  $NR^7$ .

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is  $CR^7R^8$ ;

A is S.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>;

5 The dotted line indicates the presence of either a single or double bond;

B is S;

A is O.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

25 The dotted line indicates the presence of either a single or double bond;

B is S;

A is NR<sup>7</sup>.



In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is S;

A is S.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is  $\text{NR}^7$ ;

A is O.

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

B is  $\text{NR}^7$ ;

A is  $\text{NR}^7$ .

In another sub-embodiment, a structure of the formula (VII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);


15  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;


The dotted line indicates the presence of either a single or double bond;

B is  $NR^7$ ;

20 A is S.

In a particular embodiment of the present invention, the compounds of the formula (VII) are the following species:

 (VII)							
A	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	Me	H	H	H	Me	Me
O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	Ph	H	H	H	Me	Me
O	O	Me	Me	H	H	Me	Me
O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	Ph	Me	H	H	Me	Me
O	O	Me	H	Me	H	Me	Me
O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	Ph	H	Me	H	Me	Me
O	O	Me	H	H	Me	Me	Me
O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	Ph	H	H	Me	Me	Me
O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me

<div style="text-align: center;">  <p>(VII)</p> </div>							
A	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

- 5      R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{E}$  and  $\text{B}$  are selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{G}$  is selected from the groups that include  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected

independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

$\text{B} = \text{O}$ ,  $\text{E} = \text{O}$  and  $\text{G} = \text{OR}^7$ .

5 In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{B} = \text{O}$ ,  $\text{E} = \text{NR}^8$  and  $\text{G} = \text{OR}^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$B = O, E = CR^7R^8$ , and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

20  $R^2, R^3, R^4, R^5, R^6, R^7$  and  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ .

$B = O, E = S$  and  $G = OR^7$ .



In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$B = O, E = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = O$ ,  $E = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

$B = O$ ,  $E = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

15  $B = O, E = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

35  $B = CR^7R^8, E = O$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8, E = NR^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8$ ,  $E = CR^7R^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8$ ,  $E = S$ . and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8, E = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8, E = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8, E = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = CR^7R^8$ ,  $E = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S$ ,  $E = O$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );



5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S, E = NR^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S, E = CR^7R^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S, E = S.$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S$ ,  $E = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = S$ ,  $E = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $B = S, E = CR^7R^8$  and  $G = NR^7R^8$ .

20 In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

30  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

35  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

40  $B = S, E = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7, E = O$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7$ ,  $E = NR^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7$ ,  $E = CR^7R^8$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7, E = S$  and  $G = OR^7$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7, E = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B = NR^7, E = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);



$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

5

$B = NR^7$ ,  $E = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (VIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:


$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;


$B = NR^7$ ,  $E = S$  and  $G = NR^7R^8$ .

In a particular embodiment of the present invention, the compounds of the formula (VIII) are the following species:




(VIII)

G	B	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	O	Me	H	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	O	Ph	H	H	H	Me	Me
OH	O	O	Me	Me	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	O	Ph	Me	H	H	Me	Me
OH	O	O	Me	H	Me	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	O	Ph	H	Me	H	Me	Me
OH	O	O	Me	H	H	Me	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	O	Ph	H	H	Me	Me	Me
OH	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me



(VIII)

G	B	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me

 (VIII)								
G	B	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

The dotted line indicates the presence of either a single or double bond;

$\text{E}$  is selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{G}$  is selected from the groups that include  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

The dotted line indicates the presence of either a single or double bond;

$\text{E}$  is  $\text{O}$ ;

$\text{G}$  is  $\text{OR}^7$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>.

The dotted line indicates the presence of either a single or double bond;

E is O;

G is NR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl,

heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

The dotted line indicates the presence of either a single or double bond;

E is O;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7$  and  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

The dotted line indicates the presence of either a single or double bond;

E is  $\text{CR}^7\text{R}^8$ ;

G OR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>; and

The dotted line indicates the presence of either a single or double bond;

E is CR<sup>7</sup>R<sup>8</sup>;

G is NR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);



5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15 The dotted line indicates the presence of either a single or double bond;

20 E is  $CR^7R^8$ ;

G is  $SR^7$ .

25 In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

30  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

35  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

40  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond;

E is S;

G is OR<sup>7</sup>.

5 In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

The dotted line indicates the presence of either a single or double bond;

E is S;

G is NR<sup>7</sup>R<sup>8</sup>.

25 In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is S;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is  $\text{NR}^7$ ;

G is  $\text{OR}^7$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is  $\text{NR}^7$ ;

G is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (IX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);


$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;


The dotted line indicates the presence of either a single or double bond;

E is  $NR^7$ ;

G is  $SR^7$ .


In a particular embodiment of the present invention, the compounds of the formula (IX) are the following species:

 <p>(IX)</p>							
G	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	Me	H	H	H	Me	Me
OH	O	<i>i</i> -Pr	H	H	H	Me	Me



(IX)

G	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	Ph	H	H	H	Me	Me
OH	O	Me	Me	H	H	Me	Me
OH	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	Ph	Me	H	H	Me	Me
OH	O	Me	H	Me	H	Me	Me
OH	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	Ph	H	Me	H	Me	Me
OH	O	Me	H	H	Me	Me	Me
OH	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	Ph	H	H	Me	Me	Me
OH	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	Ph	Me	H	H	Me	Me

 (IX)							
G	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	CH <sub>2</sub>	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (X) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5           A is O;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

10           R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic,

sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (X) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

A is  $\text{NR}^7$ ;

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{13}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{14}$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$  and  $\text{R}^{23}$  independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^{11}$  ( $\text{X} = \text{O}$ ,  $\text{NR}^{12}$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^{13}\text{R}^{14}$  groups, connected by a tether, independently selected from  $\text{CR}^{15}\text{R}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{CR}^{17}\text{R}^{18}$ ,  $\text{CR}^{15}=\text{CR}^{16}$ ,  $\text{CR}^{15}\text{R}^{16}\text{O}$  or  $\text{CR}^{15}\text{R}^{16}\text{NR}^{17}$ ;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In another sub-embodiment, a structure of the formula (X) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



A is S;

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>13</sup> (X = O, NR<sup>14</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup> and R<sup>23</sup> independently are selected from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphoryl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>11</sup> (X = O, NR<sup>12</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>13</sup>R<sup>14</sup> groups, connected by a tether, independently selected from CR<sup>15</sup>R<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>CR<sup>17</sup>R<sup>18</sup>, CR<sup>15</sup>=CR<sup>16</sup>, CR<sup>15</sup>R<sup>16</sup>O or CR<sup>15</sup>R<sup>16</sup>NR<sup>17</sup>;

the dotted line indicates the presence of either a single or double bond, wherein in the presence of a single bond, the valences are completed with hydrogens.

In a sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphoryl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

The dotted line indicates the presence of either a single or double bond;

$\text{E}$  is selected from the groups that include  $\text{CR}_7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{A}$  is selected from the groups that include  $\text{O}$ ,  $\text{NR}^7$  or  $\text{S}$ .

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

The dotted line indicates the presence of either a single or double bond;

$\text{E}$  is  $\text{O}$ ;

$\text{A}$  is  $\text{O}$ .

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ .

The dotted line indicates the presence of either a single or double bond;

E is O;

A is  $NR^7$ .

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl,

heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

The dotted line indicates the presence of either a single or double bond;

E is O;

A is S.

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

The dotted line indicates the presence of either a single or double bond;

E is  $\text{CR}^7\text{R}^8$ ;

A is O.

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

15  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

The dotted line indicates the presence of either a single or double bond;

20 E is  $CR^7R^8$ ;

A is  $NR^7$ .

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is  $CR^7R^8$ ;

A is S.

15 In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond;

E is S;

A is O.

5 In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is S;

A is  $NR^7$ .

25 In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is S;

A is S.

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected



independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is  $NR^7$ ;

A is O.

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

E is  $NR^7$ ;

A is  $NR^8$ .

In another sub-embodiment, a structure of the formula (XI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);


$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;


The dotted line indicates the presence of either a single or double bond;

E is  $NR^7$ ;

A is S.


In a particular embodiment of the present invention, the compounds of the formula (XI) are the following species:

 (XI)							
A	E	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$	$R^6$
O	O	Me	H	H	H	Me	Me
O	O	<i>i</i> -Pr	H	H	H	Me	Me



(XI)

A	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	Ph	H	H	H	Me	Me
O	O	Me	Me	H	H	Me	Me
O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	Ph	Me	H	H	Me	Me
O	O	Me	H	Me	H	Me	Me
O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	Ph	H	Me	H	Me	Me
O	O	Me	H	H	Me	Me	Me
O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	Ph	H	H	Me	Me	Me
O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me

 <div style="text-align: right;">(XI)</div>							
A	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5      R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

10      R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{E}$  and  $\text{D}$  are selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{A}$  is selected from the groups that include  $\text{O}$ ,  $\text{NR}^7$  or  $\text{S}$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

$\text{D} = \text{O}$ ,  $\text{E} = \text{O}$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

5  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

10  $R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ .

$D = O$ ,  $E = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

25  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

30  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$D = O$ ,  $E = CR^7R^8$ , and  $A = O$ .

5 In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

10  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

15  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ .

20  $D = O$ ,  $E = S$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl,

heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$D = O$ ,  $E = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = O$ ,  $E = NR^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:



$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

$D = O, E = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected

independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ;

$\text{D} = \text{O}$ ,  $\text{E} = \text{S}$  and  $\text{A} = \text{NR}^7$ .

5

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

10

11  
12  
13  
14  
15  
16  
17  
18  
19

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

20

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{E} = \text{O}$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8, E = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8, E = CR^7R^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $D = CR^7R^8, E = S.$  and  $A = O.$

20 In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8$ ,  $E = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8$ ,  $E = NR^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8, E = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = CR^7R^8, E = S$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl; arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

15  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $D = S, E = O$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S$ ,  $E = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S$ ,  $E = CR^7R^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );



5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S, E = S$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S, E = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S, E = NR^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S$ ,  $E = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = S$ ,  $E = S$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $D = NR^7, E = O$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = NR^7, E = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = NR^7, E = CR^7R^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

D = NR<sup>7</sup>, E = S. and A = O.

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

D = NR<sup>7</sup>, E = O and A = NR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = NR^7, E = NR^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = NR^7, E = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:


$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);


$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$D = NR^7, E = S$  and  $A = NR^7$ .

In a particular embodiment of the present invention, the compounds of the formula (XII) are the following species:


 <p style="text-align: right;">(XII)</p>								
A	D	E	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$	$R^6$
O	O	O	Me	H	H	H	Me	Me
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	O	Ph	H	H	H	Me	Me





(XII)

A	D	E	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$	$R^6$
O	O	O	Me	Me	H	H	Me	Me
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	O	Ph	Me	H	H	Me	Me
O	O	O	Me	H	Me	H	Me	Me
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	O	Ph	H	Me	H	Me	Me
O	O	O	Me	H	H	Me	Me	Me
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	O	Ph	H	H	Me	Me	Me
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	O	CH <sub>2</sub>	Me	H	Me	H	Me	Me



(XII)

A	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me

<p style="text-align: right;">(XII)</p>								
A	D	E	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>.

The dotted line indicates the presence of either a single or double bond;

D is selected from the groups that include  $CR^7R^8$ , O, S or  $NR^7$ ;

A is selected from the groups that include O,  $NR^7$  or S.

5 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

10  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

15  $R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

20 The dotted line indicates the presence of either a single or double bond;

D is O;

A is O.

25 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

The dotted line indicates the presence of either a single or double bond;

D is O;

A is  $NR^7$ .

In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

The dotted line indicates the presence of either a single or double bond;

D is O;

A is S.

5 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>.

20 The dotted line indicates the presence of either a single or double bond;

D is CR<sup>7</sup>R<sup>8</sup>;

A O.

25 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

15 The dotted line indicates the presence of either a single or double bond;

20 D is  $CR^7R^8$ ;

A is  $NR^7$ .

25 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

30  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

35  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

40  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $\text{CR}^7\text{R}^8$ ;

A is S.

5 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or S);

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or S);

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

A is O.

25 In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,



a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

A is  $\text{NR}^7$ .

In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

A is S.

In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $NR^7$ ;

A is O.

In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $NR^7$ ;

A is  $NR^8$ .

In another sub-embodiment, a structure of the formula (XIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);


$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;


5 The dotted line indicates the presence of either a single or double bond;


D is  $NR^7$ ;

A is S.

In a particular embodiment of the present invention, the compounds of the formula (XIII) are the following species:

 (XIII)							
A	D	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$	$R^6$
O	O	Me	H	H	H	Me	Me
O	O	<i>i</i> -Pr	H	H	H	Me	Me
O	O	Ph	H	H	H	Me	Me
O	O	Me	Me	H	H	Me	Me
O	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	O	Ph	Me	H	H	Me	Me
O	O	Me	H	Me	H	Me	Me
O	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	O	Ph	H	Me	H	Me	Me
O	O	Me	H	H	Me	Me	Me

<div style="text-align: center;">  <p>(XIII)</p> </div>							
A	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	O	Ph	H	H	Me	Me	Me
O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me



In a sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>.

the dotted line indicates the presence of either a single or double bond;

B is selected from the groups that include CR<sup>7</sup>R<sup>8</sup>, O, S or NR<sup>7</sup>;

G is selected from the groups that include OR<sup>7</sup>, NR<sup>7</sup>R<sup>8</sup> or SR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

the dotted line indicates the presence of either a single or double bond;

B is O;

G is  $OR^7$ .

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

the dotted line indicates the presence of either a single or double bond;

B is O;

G is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

the dotted line indicates the presence of either a single or double bond;

B is O;

G is  $\text{SR}^7$ .



In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>.

the dotted line indicates the presence of either a single or double bond;

B is CR<sup>7</sup>R<sup>8</sup>;

G OR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro,

cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}_7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

the dotted line indicates the presence of either a single or double bond;

B is  $\text{CR}^7\text{R}^8$ ;

G is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

B is  $\text{CR}^7\text{R}^8$ ;

G is SR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

10 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

15 R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>;

the dotted line indicates the presence of either a single or double bond;

20 B is S;

G is OR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);



the dotted line indicates the presence of either a single or double bond;

B is S;

G is  $SR^7$ .

5 In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

B is  $NR^7$ ;

G is  $OR^7$ .

25 In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{B}$  is  $\text{NR}^7$ ;

$\text{G}$  is  $\text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XIV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected


independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;


the dotted line indicates the presence of either a single or double bond;

B is  $NR^7$ ;

G is  $SR^7$ .

In a particular embodiment of the present invention, the compounds of the formula (XIV) are the following species:

 (XIV)							
G	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	Me	H	H	H	Me	Me
OH	O	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	Ph	H	H	H	Me	Me
OH	O	Me	Me	H	H	Me	Me
OH	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	Ph	Me	H	H	Me	Me
OH	O	Me	H	Me	H	Me	Me
OH	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	Ph	H	Me	H	Me	Me
OH	O	Me	H	H	Me	Me	Me
OH	O	<i>i</i> -Pr	H	H	Me	Me	Me

<div style="text-align: center;">  <p>(XIV)</p> </div>							
G	B	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	Ph	H	H	Me	Me	Me
OH	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	Ph	Me	H	H	Me	Me
OH	CH <sub>2</sub>	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me



In a sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

the dotted line indicates the presence of either a single or double bond;

20 B and D are selected from the groups that include  $CR^7R^8, O, S$  or  $NR^7$ ;

G is selected from the groups that include  $OR^7, NR^7R^8$  or  $SR^7$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

the dotted line indicates the presence of either a single or double bond;

$D = O, B = O$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

25  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

30 the dotted line indicates the presence of either a single or double bond;

D = O, B = NR<sup>8</sup> and G = OR<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>; and

the dotted line indicates the presence of either a single or double bond;

D = O, B = CR<sup>7</sup>R<sup>8</sup>, and G = OR<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl,

heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{O}$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{O}$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = O, B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{O}$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{O}$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = CR^7R^8, B = O$  and  $G = OR^8$ .

20 In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^8$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{OR}^8$ .



In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = CR^7R^8, B = S.$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = CR^7R^8, B = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{S}$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15 the dotted line indicates the presence of either a single or double bond;

20  $D = S, B = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

30  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

5 the dotted line indicates the presence of either a single or double bond;

$D = S$ ,  $B = CR^7R^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

20  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

25  $D = S$ ,  $B = S$ . and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = S, B = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = S$ ,  $B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = S$ ,  $B = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:



R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

the dotted line indicates the presence of either a single or double bond;

D = S, B = S and G = NR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = NR^7$ ,  $B = O$  and  $G = OR^8$ .

5

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

the dotted line indicates the presence of either a single or double bond;

$D = NR^7$ ,  $B = NR^8$  and  $G = OR^8$ .

20

25

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{S}$ . and  $\text{G} = \text{OR}^8$ .

5

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

20

25

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{NR}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

5

In another sub-embodiment, a structure of the formula (XV) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );


$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;


the dotted line indicates the presence of either a single or double bond;

$\text{D} = \text{NR}^7$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

20

In a particular embodiment of the present invention, the compounds of the formula (XV) are the following species:

								
G	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	O	Me	H	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	O	Ph	H	H	H	Me	Me
OH	O	O	Me	Me	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	O	Ph	Me	H	H	Me	Me
OH	O	O	Me	H	Me	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	O	Ph	H	Me	H	Me	Me
OH	O	O	Me	H	H	Me	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	O	Ph	H	H	Me	Me	Me
OH	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me

								
G	B	D	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me





alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

The dotted line indicates the presence of either a single or double bond;

$\text{D}$  is selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{G}$  is selected from the groups that include  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

The dotted line indicates the presence of either a single or double bond;

$\text{D}$  is  $\text{O}$ ;

$\text{G}$  is  $\text{OR}^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

The dotted line indicates the presence of either a single or double bond;

D is O;

20 G is  $NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl,

heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

The dotted line indicates the presence of either a single or double bond;

D is O;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ ).

20  $\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7$  and  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ ).

25  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

The dotted line indicates the presence of either a single or double bond;

D is  $\text{CR}^7\text{R}^8$ ;

G OR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>; and

The dotted line indicates the presence of either a single or double bond;

20 D is CR<sup>7</sup>R<sup>8</sup>;

G is NR<sup>7</sup>R<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $CR^7R^8$ ;

G is  $SR^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

G is  $OR^7$ .

5 In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

G is  $NR^7R^8$ .

25 In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is S;

G is  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected



independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $NR^7$ ;

G is  $OR^7$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $NR^7$ ;

G is  $NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVI) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

The dotted line indicates the presence of either a single or double bond;

D is  $NR^7$ ;

G is  $SR^7$ .

In a sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{D}$  and  $\text{E}$  are selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{G}$  is selected from the groups that include  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ; and

$\text{E} = \text{O}$ ,  $\text{D} = \text{O}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ .

$E = O, D = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S).

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

$\text{E} = \text{O}$ ,  $\text{D} = \text{CR}^7\text{R}^8$ , and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ .

$\text{E} = \text{O}$ ,  $\text{D} = \text{S}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

$\text{E} = \text{O}$ ,  $\text{D} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$E = O$ ,  $D = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

$E = O$ ,  $D = CR^7R^8$  and  $G = NR^7R^8$ .

20 In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

30  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester,

alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ ;

$\text{E} = \text{O}$ ,  $\text{D} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{E} = \text{CR}^7\text{R}^8$ ,  $\text{D} = \text{O}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

E = CR<sup>7</sup>R<sup>8</sup>, D = NR<sup>8</sup> and G = OR<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected

independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{E} = \text{CR}^7\text{R}^8$ ,  $\text{D} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{OR}^8$ .

5

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

20

$\text{E} = \text{CR}^7\text{R}^8$ ,  $\text{D} = \text{S}$ . and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = CR^7R^8, D = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = CR^7R^8, D = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $E = CR^7R^8, D = CR^7R^8$  and  $G = NR^7R^8$ .

20 In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

25  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

30

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

5  $E = CR^7R^8$ ,  $D = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $E = S$ ,  $D = O$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S, D = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S, D = CR^7R^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S$ ,  $D = S$ . and  $G = OR^8$ .

20 In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

25  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S$ ,  $D = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S$ ,  $D = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );



5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $E = S, D = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

20  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = S, D = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = NR^7, D = O$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = NR^7$ ,  $D = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$E = NR^7$ ,  $D = CR^7R^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

15  $E = NR^7, D = S$  and  $G = OR^8$ .

20 In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

30  $R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

35  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

40  $E = NR^7, D = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

10  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

15  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $E = NR^7$ ,  $D = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

30  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

5  $E = NR^7$ ,  $D = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $E = NR^7$ ,  $D = S$  and  $G = NR^7R^8$ .

25 In a sub-embodiment, a structure of the formula (XVIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

15 The dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens;

20  $G$  is  $OR^7$ .

25 In another sub-embodiment, a structure of the formula (XVIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

30  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

35  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

40  $R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected

independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens;

G is  $NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XVIII) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

The dotted line indicates the presence of either a single or double bond, wherein the presence of a single bond, the valences are completed by hydrogens;

G is  $SR^7$ .



In a sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$ , and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$B$  and  $M$  are selected from the groups that include  $CR^7R^8, O, S$  or  $NR^7$ ; and

$A$  is selected from the groups that include  $O, NR^7$  or  $S$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ ).

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected

independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ .

B and M are selected from the groups that include  $CR^7R^8$ , O, S or  $NR^7$ ;

A is selected from the groups that include O,  $NR^7$  or S.

5

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S).

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or S);

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

$M = O$ ,  $B = O$  and  $A = O$ .

20

25

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{M} = \text{O}$ ,  $\text{B} = \text{NR}^8$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$M = O$ ,  $B = CR^7R^8$ , and  $A = O$ .

5 In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

10  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

15  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ .

20  $M = O$ ,  $B = S$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$M = O, B = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

M = O, B = NR<sup>8</sup> and A = NR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

5 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

10 R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

15 R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub> and R<sub>5</sub> and R<sub>6</sub> can also each be comprised of one or two CR<sub>7</sub>R<sub>8</sub> groups, connected by a tether, selected independently from groups that include CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>CR<sub>7</sub>R<sub>8</sub>, CR<sub>7</sub>=CR<sub>8</sub>, CR<sub>7</sub>R<sub>8</sub>O and CR<sub>7</sub>R<sub>8</sub>NR<sub>7</sub>;

20 M = O, B = CR<sup>7</sup>R<sup>8</sup> and A = NR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

25 R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

30 R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

5  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = O$ ,  $B = S$  and  $A = NR^7$ .

10 In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

15  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8$ ,  $B = O$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8, B = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,



carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{S}$ . and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8, B = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8$ ,  $B = NR^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8$ ,  $B = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{S}$  and  $\text{A} = \text{NR}^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

M = S, B = O and A = O.

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

M = S, B = NR<sup>8</sup> and A = O.

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{S}$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = S, B = O$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{NR}^8$  and  $\text{A} = \text{NR}^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{A} = \text{NR}^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:



R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

M = S, B = S and A = NR<sup>7</sup>.

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = O$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = NR^8$  and  $A = O$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{NR}^7$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{A} = \text{O}$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = S$ . and  $A = O$ .

5 In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = O$  and  $A = NR^7$ .

25 In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7, B = NR^8$  and  $A = NR^7$ .

15 In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = CR^7R^8$  and  $A = NR^7$ .

In another sub-embodiment, a structure of the formula (XIX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug is defined as follows:


5  $R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );


10  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

15  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $M = NR^7$ ,  $B = S$  and  $A = NR^7$ .

In a particular embodiment of the present invention, the compounds of the formula (XIX) are the following species:

<div style="text-align: center;">  <p>(XIX)</p> </div>									
A	B	M	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	
O	O	O	Me	H	H	H	Me	Me	
O	O	O	<i>i</i> -Pr	H	H	H	Me	Me	
O	O	O	Ph	H	H	H	Me	Me	
O	O	O	Me	Me	H	H	Me	Me	
O	O	O	<i>i</i> -Pr	Me	H	H	Me	Me	
O	O	O	Ph	Me	H	H	Me	Me	
O	O	O	Me	H	Me	H	Me	Me	
O	O	O	<i>i</i> -Pr	H	Me	H	Me	Me	
O	O	O	Ph	H	Me	H	Me	Me	
O	O	O	Me	H	H	Me	Me	Me	
O	O	O	<i>i</i> -Pr	H	H	Me	Me	Me	
O	O	O	Ph	H	H	Me	Me	Me	
O	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me	
O	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me	
O	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me	
O	CH <sub>2</sub>	O	Me	H	H	H	Me	Me	
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me	



(XIX)

A	B	M	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
O	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
O	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
O	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
O	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

In a sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

5

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,



a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}_1$  and  $\text{R}_2$ ,  $\text{R}_2$  and  $\text{R}_3$ ,  $\text{R}_3$  and  $\text{R}_4$ ,  $\text{R}_4$  and  $\text{R}_5$  and  $\text{R}_5$  and  $\text{R}_6$  can also each be comprised of one or two  $\text{CR}_7\text{R}_8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}_7\text{R}_8$ ,  $\text{CR}_7\text{R}_8\text{CR}_7\text{R}_8$ ,  $\text{CR}_7=\text{CR}_8$ ,  $\text{CR}_7\text{R}_8\text{O}$  and  $\text{CR}_7\text{R}_8\text{NR}_7$ .

$\text{B}$  and  $\text{M}$  are selected from the groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{O}$ ,  $\text{S}$  or  $\text{NR}^7$ ;

$\text{G}$  is selected from the groups that include  $\text{OR}^7$ ,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ; and

$M = O$ ,  $B = O$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ ).

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ .

$M = O$ ,  $B = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,

a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ; and

$\text{M} = \text{O}$ ,  $\text{B} = \text{CR}^7\text{R}^8$ , and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ .

$M = O$ ,  $B = S$  and  $G = OR^8$ .

5

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ; and

$M = O$ ,  $B = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = O, B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R_1$  and  $R_2, R_2$  and  $R_3, R_3$  and  $R_4, R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8, CR_7R_8CR_7R_8, CR_7=CR_8, CR_7R_8O$  and  $CR_7R_8NR_7$ ;

$M = O$ ,  $B = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_5$  and  $R_5$  and  $R_6$  can also each be comprised of one or two  $CR_7R_8$  groups, connected by a tether, selected independently from groups that include  $CR_7R_8$ ,  $CR_7R_8CR_7R_8$ ,  $CR_7=CR_8$ ,  $CR_7R_8O$  and  $CR_7R_8NR_7$ ;

$M = O$ ,  $B = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{NR}^8$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8, B = CR^7R^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,



carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{S}$ . and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{CR}^7\text{R}^8$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8, B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8$ ,  $B = CR^7R^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = CR^7R^8$ ,  $B = S$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

M = S, B = O and G = OR<sup>8</sup>.

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

R<sup>1</sup> is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S);

R<sup>1</sup> and R<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>4</sup> and R<sup>5</sup> and R<sup>5</sup> and R<sup>6</sup> can also each be comprised of one or two CR<sup>7</sup>R<sup>8</sup> groups, connected by a tether, selected independently from groups that include CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>CR<sup>7</sup>R<sup>8</sup>, CR<sup>7</sup>=CR<sup>8</sup>, CR<sup>7</sup>R<sup>8</sup>O and CR<sup>7</sup>R<sup>8</sup>NR<sup>7</sup>;

$M = S$ ,  $B = NR^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = S$ ,  $B = CR^7R^8$  and  $G = OR^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{S}$ . and  $\text{G} = \text{OR}^8$ .

10 In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

15  $\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

20  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

25  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^2, R^3, R^4, R^5, R^6, R^7, R^8$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = S, B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or S);

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl,

carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{S}$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide,



a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{NR}^7$ ,  $\text{B} = \text{O}$  and  $\text{G} = \text{OR}^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ );

$\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected

independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = NR^8$  and  $G = OR^8$ .

5 In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

10  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

15  $R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

20  $M = NR^7$ ,  $B = CR^7R^8$  and  $G = OR^8$ .

25 In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

5  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

10  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7, B = S.$  and  $G = OR^8$ .

15 In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

20  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O, NR^8$  or  $S$ );

25  $R^1$  and  $R^2, R^2$  and  $R^3, R^3$  and  $R^4, R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8, CR^7R^8CR^7R^8, CR^7=CR^8, CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = O$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$  and  $R^2$ ,  $R^2$  and  $R^3$ ,  $R^3$  and  $R^4$ ,  $R^4$  and  $R^5$  and  $R^5$  and  $R^6$  can also each be comprised of one or two  $CR^7R^8$  groups, connected by a tether, selected independently from groups that include  $CR^7R^8$ ,  $CR^7R^8CR^7R^8$ ,  $CR^7=CR^8$ ,  $CR^7R^8O$  and  $CR^7R^8NR^7$ ;

$M = NR^7$ ,  $B = NR^8$  and  $G = NR^7R^8$ .

In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:

$R^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $XR^7$  ( $X = O$ ,  $NR^8$  or  $S$ );

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl,

sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

5  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;

$\text{M} = \text{NR}^7$ ,  $\text{B} = \text{CR}^7\text{R}^8$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

10 In another sub-embodiment, a structure of the formula (XX) is given wherein the compound or its pharmaceutically acceptable salts or prodrug are defined as follows:


$\text{R}^1$  is selected independently from the groups that include hydrogen, alkyl, cycloalkyl, aryl, alkaryl, arylalkyl, heterocyclic, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

15  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$ ,  $\text{R}^{15}$ ,  $\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$  and  $\text{R}^{19}$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkaryl, arylalkyl, heterocyclic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, halide, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}, \text{NR}^8$  or  $\text{S}$ );

20  $\text{R}^1$  and  $\text{R}^2$ ,  $\text{R}^2$  and  $\text{R}^3$ ,  $\text{R}^3$  and  $\text{R}^4$ ,  $\text{R}^4$  and  $\text{R}^5$  and  $\text{R}^5$  and  $\text{R}^6$  can also each be comprised of one or two  $\text{CR}^7\text{R}^8$  groups, connected by a tether, selected independently from groups that include  $\text{CR}^7\text{R}^8$ ,  $\text{CR}^7\text{R}^8\text{CR}^7\text{R}^8$ ,  $\text{CR}^7=\text{CR}^8$ ,  $\text{CR}^7\text{R}^8\text{O}$  and  $\text{CR}^7\text{R}^8\text{NR}^7$ ;


25  $\text{M} = \text{NR}^7$ ,  $\text{B} = \text{S}$  and  $\text{G} = \text{NR}^7\text{R}^8$ .

In a particular embodiment of the present invention, the compounds of the formula (XX) are the following species:

 (XX)								
G	B	M	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	O	Me	H	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	O	Ph	H	H	H	Me	Me
OH	O	O	Me	Me	H	H	Me	Me
OH	O	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	O	Ph	Me	H	H	Me	Me
OH	O	O	Me	H	Me	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	O	Ph	H	Me	H	Me	Me
OH	O	O	Me	H	H	Me	Me	Me
OH	O	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	O	Ph	H	H	Me	Me	Me
OH	O	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	H	Me	Me

(XX)

G	B	M	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	CH <sub>2</sub>	O	Ph	H	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	Me	H	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	Me	H	Me	Me
OH	CH <sub>2</sub>	O	Me	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	H	Me	Me	Me
OH	CH <sub>2</sub>	O	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	CH <sub>2</sub>	O	Ph	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	Me	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	H	H	Me	Me
OH	O	CH <sub>2</sub>	Me	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	Me	H	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	Me	H	H	Me	Me

 (XX)								
G	B	M	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
OH	O	CH <sub>2</sub>	Me	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	Me	H	Me	Me
OH	O	CH <sub>2</sub>	Me	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	H	Me	Me	Me
OH	O	CH <sub>2</sub>	Me	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	<i>i</i> -Pr	H	CH <sub>2</sub> Ph	H	Me	Me
OH	O	CH <sub>2</sub>	Ph	H	CH <sub>2</sub> Ph	H	Me	Me

## II. Definitions

It should be understood that the various possible stereoisomers of the groups mentioned above and herein are within the meaning of the individual terms and examples, unless otherwise specified. As an illustrative example, "1-methyl-butyl" exists in both the (R) and the (S) form, thus, both (R)-1-methyl-butyl and (S)-1-methyl-butyl is covered by the term "1-methyl-butyl," unless otherwise specified. Several biological compounds are designed by the (D) and the (L) form, rather than the (R) and the (S) form, respectively, based on the stereochemistry around the 4' carbon. As an another illustrative example, "glycine" exists in both the (D) and the (L) form; therefore, both (D)-glycine and (L)-glycine are covered by the term "glycine" unless otherwise specified.



As used herein, the term "isolated enantiomer" refers to a composition that includes at least approximately 95% to 100%, or more preferably, over 97% of a single enantiomer of that compound.

As used herein, the term "substantially free of" or "substantially in the absence of" refers to a composition that includes at least 85 or 90% by weight, preferably 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that compound.

The term "independently" is used herein to indicate that the variable that is independently applied varies independently from application to application. Thus, in a compound such as R"XYR", wherein R" is "independently carbon or nitrogen," both R" can be carbon, both R" can be nitrogen, or one R" can be carbon and the other R" nitrogen.

The term alkyl, as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon, typically of C<sub>1</sub> to C<sub>18</sub> and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexylisohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2, 2-dimethylbutyl and 2,3-dimethylbutyl. The alkyl group can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, thiol, imine, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphate, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term lower alkyl, as used herein, and unless otherwise specified, refers to a C<sub>1</sub> to C<sub>4</sub> saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms.

The term alkylene or alkenyl refers to a saturated hydrocarbyldiyl radical of straight or branched configuration, including but not limited to those that have from one to

ten carbon atoms. Included within the scope of this term are methylene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, 1,4-butane-diyl and the like. The alkylene group or other divalent moiety disclosed herein can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "protected" as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art or organic synthesis. Suitable protecting groups are described, for example, in Greene, *et al.*, "Protective Groups in Organic Synthesis," John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term aryl, as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl, and preferably phenyl. The aryl group can be optionally substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, halo, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, "Protective Groups in Organic Synthesis," John Wiley and Sons, Second Edition, 1991.

The term aralkyl, as used herein, and unless otherwise specified, refers to an aryl group as defined above linked to the molecule through an alkyl group as defined above. The term alkaryl or alkylaryl as used herein, and unless otherwise specified, refers to an alkyl group as defined above linked to the molecule through an aryl group as defined above. In each of these groups, the alkyl group can be optionally substituted as describe above and the aryl group can be optionally substituted with one or more moieties selected

from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included within the scope of the term aryl are phenyl; naphthyl; phenylmethyl; phenylethyl; 3,4,5-trihydroxyphenyl; 3,4,5-trimethoxyphenyl; 3,4,5-triethoxyphenyl; 4-chlorophenyl; 4-methylphenyl; 3,5-di-tertiarybutyl-4-hydroxyphenyl; 4-fluorophenyl; 4-chloro-1-naphthyl; 2-methyl-1-naphthylmethyl; 2-naphthylmethyl; 4-chlorophenylmethyl; 4-tertiarybutylphenyl; 4-tertiarybutylphenylmethyl and the like.

The term halo or halogen, as used herein includes chloro, bromo, iodo and fluoro.

The term heteroatom, as used herein, refers to oxygen, sulfur, nitrogen or phosphorus.

The term alkylamino or arylamino refers to an amino group that has one or two alkyl or aryl substituents, respectively.

The term alkoxy, as used herein, and unless otherwise specified, refers to a moiety of the structure -O-alkyl, wherein alkyl is as defined above.

The term acyl refers to moiety of the formula -C(O)R', wherein R' is alkyl; aryl, alkaryl, aralkyl, heteroaromatic, heterocyclic, alkoxyalkyl including methoxymethyl; arylalkyl including benzyl; aryloxyalkyl, such as phenoxymethyl; aryl including phenyl optionally substituted with halo groups C<sub>1</sub> to C<sub>4</sub> alkyl or C<sub>1</sub> to C<sub>4</sub> alkoxy or the residue of an amino acid.

As used herein, a leaving group means a functional group that is cleaved from the molecule to which it is attached under appropriate conditions.

The term heteroaryl or heteroaromatic, as used herein, refers to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring. The term

heterocyclic refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen or phosphorus in the ring. Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, or imidazole. The heteroaromatic group can be optionally substituted as described above for aryl. The heterocyclic group can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, and *t*-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.

The term amino acid includes naturally occurring and synthetic amino acids, and includes but is not limited to, alanyl, valinyl, leucinyl, isoleuccinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl and histidinyl.

The term "ether," as used herein, refers to oxygen that is disubstituted with independent alkyl groups or two alkyl groups that together formed a ring or a bridge. Some non-limiting examples include 4-(tetrahydrobenzimidazol-1-yl)butoxy, 5-(tetra-

hydrobenzimidazol-1-yl)pentoxy, ethoxy, n-propoxy or isopropoxy. The ethers also can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "amide," as used herein, refers to a carbonyl moiety wherein the non-alkyl moiety is formed from an amine. Some non-limiting examples are formylamino, acetylamino, propionylamino, butanoylamino, isobutanoylamino, pentanoylamino, 3-methyl-butanoylamino, hexanoylamino, methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, benzamido, cyclopentylcarbonylamido, cyclohexylcarbonylamido, cycloheptylcarbonylamido, phenylacetylamido, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "sulfamoyl" is a hexavalent sulfur covalently bound to at least two oxygens and a nitrogen. Some non-limiting examples include methanesulphonylamino, ethanesulphonylamino, n-propanesulphonylamino, isopropanesulphonylamino, n-butanesulphonylamino, N-ethyl-phenylmethanesulphonylamido, N-ethyl-2-phenylethanesulphonylamido, N-ethyl-3-phenylpropanesulphonylamido, N-ethyl-naphthalen-1-ylsulphonamido or N-ethyl-naphthalen-2-yl-sulphonylamido. The sulfamoyl group also can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide,

anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "thio" refers to a sulfur covalently bound to a hydrogen or a carbon based group. Some non-limiting examples include methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto or n-butylmercapto, ethylthio, n-propylthio or isopropylthio group. The thio group also can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "ester" refers to a carbonyl flanked by an alkoxy group and a carbon based group. Some non-limiting examples include hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, isobutyloxycarbonyl, tert-butyloxycarbonyl or 1-(cinnamyloxycarbonyloxy)-ethoxycarbonyl. The ester group also can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*,

Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term "urethane" or "carbamate" refers to  $-\text{OC}(\text{O})\text{NR}^4\text{R}^5$  in which  $\text{R}^4$  and  $\text{R}^5$  are independently selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen,  $\text{C}_1$  to  $\text{C}_4$  alkyl or  $\text{C}_1$  to  $\text{C}_4$  alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-*t*-butylsilyl) or diphenylmethylsilyl. Aryl groups in the carbamide optimally comprise a phenyl group. The term "lower carbamide" refers to an carbamide group in which the non-carbonyl moiety is a lower alkyl. The carbamide group also can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*, Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term carbohydrate, used herein refers to mono, di, tri, oligo, and poly saccharides consisting of furanose and pyranose sugars such as threose, ribulose, ketose, gentiobiose, aldose, aldotetrose, aldopentose, aldohexose, ketohexose, ketotetrose, ketopentose, erythrose, threose, ribose, deoxyribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, dextrose, maltose, lactose, sucrose, or cellulose. The carbohydrate moiety as disclosed herein can be optionally substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl,

phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, *et al.*,  
5 Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.

The term alkylheteroaryl refers to an alkyl group substituted by a heteroaryl substituent.

10 The term host, as used herein, refers to a multicellular organism in which the symptoms of an autoimmune or inflammatory disorder, including animals, and preferably a human. The term host specifically refers to animals, in particular, primates (including chimpanzees) and humans, in which autoimmune and inflammatory disorders occur. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present  
15 invention (such as chimpanzees).

### III. Pharmaceutically Acceptable Salt Formulations

20 Modifications of the active compound can affect the bioavailability and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its activity according to the methods described herein, or other method known to those skilled in the art.

25 In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. The term "pharmaceutically acceptable salts" or "complexes" refers to salts or complexes that retain the desired biological activity of the compounds of the present invention and exhibit minimal undesired toxicological effects.

Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate,



methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate,  $\alpha$ -ketoglutarate and  $\alpha$ -glycerophosphate. Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate and carbonate salts. Alternatively, the pharmaceutically acceptable salts may be made with sufficiently basic compounds such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

Nonlimiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pantoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; (b) base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed from ammonia, N,N-dibenzylethylenediamine, D-glucosamine, tetraethylammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like. Also included in this definition are pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula  $-NR^+A^-$ , wherein R is as defined above and A is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzyloate, and diphenylacetate).

Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess anti-inflammatory activity, or are metabolized to a compound that exhibits such activity.

Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the compound. A number of prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the compound will increase the stability of the compound. Examples of substituent groups that can replace one or more hydrogens on the compound are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, *Antiviral Research*, 27 (1995) 1-17. Any of these can be used in combination with the disclosed compounds to achieve a desired effect.

#### IV. Autoimmune and Inflammatory Diseases

The compounds of the present invention can be used to treat any disorder that is mediated by LO. Dysfunction in LO production is implicated in a wide variety of disease states, including but not limited to arthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, and conjunctivitis.

Nonlimiting examples of arthritis include rheumatoid (such as soft-tissue rheumatism and non-articular rheumatism, fibromyalgia, fibrositis, muscular rheumatism, myofascil pain, humeral epicondylitis, frozen shoulder, Tietze's syndrome, fascitis, tendinitis, tenosynovitis, bursitis), juvenile chronic, spondyloarthropaties (ankylosing spondylitis), osteoarthritis, hyperuricemia and arthritis associated with acute gout, chronic gout and systemic lupus erythematosus.

Human endothelial disorders mediated by LO include psoriasis, eczematous dermatitis, Kaposi's sarcoma as well as proliferative disorders of smooth muscle cells.

In yet another embodiment, the compounds disclosed herein can be selected to treat anti-inflammatory conditions that are mediated by mononuclear leukocytes.

In one embodiment, the compounds of the present invention are selected for the prevention or treatment of tissue or organ transplant rejection. Treatment and prevention of organ or tissue transplant rejection includes, but are not limited to treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, spleen, small bowel, or corneal transplants. The compounds can also be used in the prevention or treatment of graft-versus-host disease, such as sometimes occurs following bone marrow transplantation.

## V. Combination and Alternation Therapy

Any of the compounds disclosed herein can be administered in combination or alternation with a second biologically active agent to increase its effectiveness against the target disorder.

In combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

The efficacy of a drug can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, agent that induces a different biological pathway from that caused by the principle drug. Alternatively, the pharmacokinetics, biodistribution or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the condition.

Any method of alternation can be used that provides treatment to the patient. Nonlimiting examples of alternation patterns include 1-6 weeks of administration of an effective amount of one agent followed by 1-6 weeks of administration of an effective

amount of a second agent. The alternation schedule can include periods of no treatment. Combination therapy generally includes the simultaneous administration of an effective ratio of dosages of two or more active agents.

Illustrative examples of specific agents that can be used in combination or alternation with the compounds of the present invention are described below in regard to asthma and arthritis. The agents set out below or others can alternatively be used to treat a host suffering from any of the other disorders listed in Section IV or that are mediated by LO, and preferably 15-LO.

### *Asthma*

In one embodiment, the compound of the present invention is administered in combination or alternation with heparin, frusemide, ranitidine, an agent that effects respiratory function, such as DNAase, or immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds such as Myochrysine (gold sodium thiomalate), platelet activating factor (PAF) antagonists such as thromboxane inhibitors, leukotriene-D<sub>4</sub>-receptor antagonists such as Accolate (zafirlukast), Ziflo (zileuton), leukotriene C<sub>1</sub> or C<sub>2</sub> antagonists and inhibitors of leukotriene synthesis such as zileuton for the treatment of asthma, or an inducible nitric oxide synthase inhibitor.

In another embodiment, the active compound is administered in combination or alternation with one or more other prophylactic agent(s). Examples of prophylactic agents that can be used in alternation or combination therapy include but are not limited to sodium cromoglycate, Intal (cromolyn sodium, Nasalcrom, Opticrom, Crolom, Ophthalmic Crolom), Tilade (nedocromil, nedocromil sodium) and ketotifen.

In another embodiment, the active compound is administered in combination or alternation with one or more other  $\beta_2$ -adrenergic agonist(s) ( $\beta$  agonists). Examples of  $\beta_2$ -adrenergic agonists ( $\beta$  agonists) that can be used in alternation or combination therapy include but are not limited to albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate,

broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirmoterol fumarate, ephedra (source of alkaloids), ephedrine (ephedrine hydrochloride, ephedrine sulfate), etafedrine hydrochloride, ethylnoradrenaline hydrochloride, fenoterol hydrochloride, hexoprenaline hydrochloride, isoetharine hydrochloride, isoprenaline, mabuterol, methoxyphenamine hydrochloride, methylephedrine hydrochloride, orciprenaline sulphate, phenylephrine acid tartrate, phenylpropanolamine (phenylpropanolamine polistirex, phenylpropanolamine sulphate), pirbuterol acetate, procaterol hydrochloride, protokylol hydrochloride, psuedoephedrine (psuedoephedrine polixtirex, psuedoephedrine tannate, psuedoephedrine hydrochloride, psuedoephedrine sulphate), reproterol hydrochloride, rimiterol hydrobromide, ritodrine hydrochloride, salmeterol xinafoate, terbutaline sulphate, tretoquinol hydrate and tulobuterol hydrochloride.

In another embodiment, the active compound is administered in combination or alternation with one or more other corticosteriod(s). Examples of corticosteriods that can be used in alternation or combination therapy include but are not limited to glucocorticoids (GC), Aerobid (Aerobid-M, flunisolide), Azmacort (triamcinolone acetonide), Beclovet (Vanceril, beclomethasone dipropionate), Flovent (fluticasone), Pulmicort (budesonide), prednisolone, hydrocortisone, adrenaline, Alclometasone Dipropionate, Aldosterone, Amcinonide, Beclomethasone Dipropionate, Bendacort, Betamethasone (Betamethasone Acetate, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Betamethasone Valerate), Budesonide, Ciclomethasone, Ciprocinnonide, Clobetasol Propionate, Clobetasone Butyrate, Clocortolone Pivalate, Cloprednol, Cortisone Acetate, Cortivazol, Deflazacort, Deoxycortone Acetate (Deoxycortone Pivalate), Deprodone, Desonide, Desoxymethasone, Dexamethasone (Dexamethasone Acetate, Dexamethasone Isonicotinate, Dexamethasone Phosphate, Dexamethasone Sodium Metasulphobenzoate, Dexamethasone Sodium Phosphate), Dichlorisone Acetate, Diflorasone Diacetate, Diflucortolone Valerate, Difluprednate, Domoprednate, Endrysone, Fluazacort, Fluclorolone Acetonide, Fludrocortisone Acetate, Flumethasone (Flumethasone Pivalate), Flunisolide, Fluocinolone Acetonide, Fluocinnonide, Fluocortin Butyl, Fluocortolone (Fluocortolone Hexanoate, Fluocortolone Pivalate), Fluorometholone (Fluorometholone Acetate), Fluprednidene Acetate, Fluprednisolone, Flurandrenolone, Fluticasone Propionate, Formocortol, Halcinnonide, Halobetasol Propionate, Halometasone, Hydrocortamate Hydrochloride, Hydrocortisone (Hydrocortisone Acetate, Hydrocortisone

Butyrate, Hydrocortisone Cypionate, Hydrocortisone Hemisuccinate, Hydrocortisone Sodium Phosphate, Hydrocortisone Sodium Succinate, Hydrocortisone Valerate), Medrysone, Meprednisone, Methylprednisolone (Methylprednisolone Acetate, Methylprednisolone Hemisuccinate, Methylprednisolone Sodium Succinate),  
5 Mometasone Furoate, Paramethasone Acetate, Prednicarbate, Prednisolamate Hydrochloride, Prednisolone (Prednisolone Acetate, Prednisolone Hemisuccinate, Prednisolone Hexanoate, Prednisolone Pivalate, Prednisolone Sodium Metasulphobenzoate, Prednisolone Sodium Phosphate, Prednisolone Sodium Succinate, Prednisolone Steaglate, Prednisolone Tebutate), Prednisone (Prednisone Acetate),  
10 Prednylidene, Procinonide, Rimexolone, Suprarenal Cortex, Tixocortol Pivalate, Triamcinolone (Triamcinolone Acetonide, Triamcinolone Diacetate and Triamcinolone Hexacetonide).

In another embodiment, the active compound is administered in combination or alternation with one or more other antihistamine(s) (H<sub>1</sub> receptor antagonists). Examples of antihistamines (H<sub>1</sub> receptor antagonists) that can be used in alternation or combination therapy include alkylamines, ethanolamines, ethylenediamines, piperazines, piperidines or phenothiazines. Some non-limiting examples of antihistamines are Chlortrimeton (Teldrin, chlorpheniramine), Atrohist (brompheniramine, Bromarest, Bromfed, Dimetane), Actidil (triprolidine), Dexchlor (Poladex, Polaramine, dexchlorpheniramine), Benadryl (diphen-hydramine), Tavist (clemastine), Dimetabs (dimenhydrinate, Dramamine, Marmine), PBZ (tripelennamine), pyrilamine, Marezine (cyclizine), Zyrtec (cetirizine), hydroxyzine, Antivert (meclizine, Bonine), Allegra (fexofenadine), Hismanal (astemizole), Claritin (loratadine), Seldane (terfenadine), Periactin (cyproheptadine), Nalamine (phenindamine, Nolahist), Phenameth (promethazine, Phenergan), Tacaryl (methdilazine) and Temaril (trimeprazine).  
25

Alternatively, the compound of the present invention is administered in combination or alternation with

(a) xanthines and methylxanthines, such as Theo-24 (theophylline, Slo-Phylline, Uniphyllin, Slobid, Theo-Dur), Choledyl (oxitriphylline), aminophylline;

(b) anticholinergic agents (antimuscarinic agents) such as belladonna alkaloids, Atrovent (ipratropium bromide), atropine, oxitropium bromide;

(c) phosphodiesterase inhibitors such as zardaverine;

- (d) calcium antagonists such as nifedipine; or
- (e) potassium activators such as cromakalim for the treatment of asthma.

### ***Arthritic disorders***

In one embodiment, the compound of the present invention can also be administered in combination or alternation with apazone, amitriptyline, chymopapain, collagenase, cyclobenzaprine, diazepam, fluoxetine, pyridoxine, ademetonine, diacerein, glucosamine, hylan (hyaluronate), misoprostol, paracetamol, superoxide dismutase mimics, TNF $\alpha$  receptor antagonists, TNF $\alpha$  antibodies, P38 Kinase inhibitors, tricyclic antidepressants, cJun kinase inhibitors or immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds such as Myochrysine (gold sodium thiomalate), platelet activating factor (PAF) antagonists such as thromboxane inhibitors, leukotriene-D<sub>4</sub>-receptor antagonists such as Accolate (zafirlukast), Ziflo (zileuton), leukotriene C<sub>1</sub>, C<sub>2</sub> antagonists and inhibitors of leukotriene synthesis such as zileuton for the treatment of arthritic disorders, inducible nitric oxide synthase inhibitors.

In another embodiment, the active compound is administered in combination or alternation with one or more other corticosteroid(s). Examples of corticosteroids that can be used in alternation or combination therapy include but are not limited to glucocorticoids (GC), Aerobid (Aerobid-M, flunisolide), Azmacort (triamcinolone acetonide), Beclovet (Vanceril, beclomethasone dipropionate), Flovent (fluticasone), Pulmicort (budesonide), prednisolone, hydrocortisone, adrenaline, Alclometasone Dipropionate, Aldosterone, Amcinonide, Beclomethasone Dipropionate, Bendacort, Betamethasone (Betamethasone Acetate, Betamethasone Benzoate, Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Betamethasone Valerate), Budesonide, Ciclomethasone, Ciprocinnonide, Clobetasol Propionate, Clobetasone Butyrate, Clocortolone Pivalate, Cloprednol, Cortisone Acetate, Cortivazol, Deflazacort, Deoxycortone Acetate (Deoxycortone Pivalate), Deprodone, Desonide, Desoxymethasone, Dexamethasone (Dexamethasone Acetate, Dexamethasone Isonicotinate, Dexamethasone Phosphate, Dexamethasone Sodium Metasulphobenzoate, Dexamethasone Sodium Phosphate), Dichlorisone Acetate, Diflorasone Diacetate, Diflucortolone Valerate, Difluprednate, Domoprednate, Endrysone,

Fluazacort, Fluclorolone Acetonide, Fludrocortisone Acetate, Flumethasone (Flumethasone Pivalate), Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluocortin Butyl, Fluocortolone (Fluocortolone Hexanoate, Fluocortolone Pivalate), Fluorometholone (Fluorometholone Acetate), Fluprednidene Acetate, Fluprednisolone, Flurandrenolone, Fluticasone Propionate, Formocortal, Halcinonide, Halobetasol Propionate, Halometasone, Hydrocortamate Hydrochloride, Hydrocortisone (Hydrocortisone Acetate, Hydrocortisone Butyrate, Hydrocortisone Cypionate, Hydrocortisone Hemisuccinate, Hydrocortisone Sodium Phosphate, Hydrocortisone Sodium Succinate, Hydrocortisone Valerate), Medrysone, Meprednisone, Methylprednisolone (Methylprednisolone Acetate, Methylprednisolone Hemisuccinate, Methylprednisolone Sodium Succinate), Mometasone Furoate, Paramethasone Acetate, Prednicarbate, Prednisolamate Hydrochloride, Prednisolone (Prednisolone Acetate, Prednisolone Hemisuccinate, Prednisolone Hexanoate, Prednisolone Pivalate, Prednisolone Sodium Metasulphobenzoate, Prednisolone Sodium Phosphate, Prednisolone Sodium Succinate, Prednisolone Steaglate, Prednisolone Tebutate), Prednisone (Prednisone Acetate), Prednylidene, Procinonide, Rimexolone, Suprarenal Cortex, Tixocortol Pivalate, Triamcinolone (Triamcinolone Acetonide, Triamcinolone Diacetate and Triamcinolone Hexacetonide).

In another embodiment, the active compound is administered in combination or alternation with one or more other non-steroidal anti-inflammatory drug(s) (NSAIDS). Examples of NSAIDS that can be used in alternation or combination therapy are carboxylic acids, propionic acids, fenamates, acetic acids, pyrazolones, oxicans, alkanones, gold compounds and others that inhibit prostaglandin synthesis, preferably by selectively inhibiting cyclooxygenase-2 (COX-2). Some nonlimiting examples of COX-2 inhibitors are Celebrex (celecoxib) and Vioxx (rofecoxib). Some non-limiting examples of NSAIDS are aspirin (acetylsalicylic acid), Dolobid (diflunisal), Disalcid (salsalate, salicylsalicylate), Trisilate (choline magnesium trisalicylate), sodium salicylate, Cuprimine (penicillamine), Tolectin (tolmetin), ibuprofen (Motrin, Advil, Nuprin Rufen), Naprosyn (naproxen, Anaprox, naproxen sodium), Nalfon (fenoprofen), Orudis (ketoprofen), Ansaid (flurbiprofen), Daypro (oxaprozin), meclofenamate (meclofenamic acid, Meclomen), mefenamic acid, Indocin (indomethacin), Clinoril (sulindac), tolmetin, Voltaren (diclofenac), Lodine (etodolac), ketorolac, Butazolidin (phenylbutazone), Tandearil (oxyphenbutazone), piroxicam (Feldene), Relafen (nabumetone), Myochrysine



(gold sodium thiomalate), Ridaura (auranofin), Solganal (aurothioglucose), acetaminophen, colchicine, Zylprim (allopurinol), Benemid (probenecid), Anturane (sufinpyrzone), Plaquenil (hydroxychloroquine), Aceclofenac, Acemetacin, Acetanilide, Actarit, Alclofenac, Alminoprofen, Aloxiprin, Aluminium Aspirin, Amfenac Sodium, Amidopyrine, Aminopropylone, Ammonium Salicylate, Ampiroxicam, Amyl Salicylate, Aniolac, Aspirin, Auranofin, Aurothioglucose, Aurotioprol, Azapropazone, Bendazac (Bendazac Lysine), Benorylate, Benoxaprofen, Benzpiperylone, Benzydamine hydrochloride, Bornyl Salicylate, Bromfenac Sodium, Bufexamac, Bumadizone Calcium, Butibufen Sodium, Capsaicin, Carbaspirin Calcium, Carprofen, Chlorthenoxazin, Choline Magnesium Trisalicylate, Choline Salicylate, Cinmetacin, Clofexamide, Clofezone, Clometacin, Clonixin, Cloracetadol, Cymene, Diacerein, Diclofenac (Diclofenac Diethylammonium Salt, Diclofenac Potassium, Diclofenac Sodium), Diethylamine Salicylate, Diethylsalicylamide, Difenpiramide, Diflunisal, Dipyrone, Droxicam, Epirizole, Etenzamide, Etersalate, Ethyl Salicylate, Etodolac, Etofenamate, Felbinac, Fenbufen, Fenclofenac, Fenoprofen Calcium, Fentiazac, Fepradinol, Feprazone, Floctafenine, Flufenamic, Flunoxaprofen, Flurbiprofen (Flurbiprofen Sodium), Fosfosal, Furprofen, Glafenine, Glucametacin, Glycol Salicylate, Gold Keratinate, Harpagophytum Procumbens, Ibufenac, Ibuprofen, Ibuproxam, Imidazole Salicylate, Indomethacin (Indomethacin Sodium), Indoprofen, Isamifazone, Isonixin, Isoxicam, Kebuzone, Ketoprofen, Ketorolac Trometamol, Lithium Salicylate, Lonazolac Calcium, Lornoxicam, Loxoprofen Sodium, Lysine Aspirin, Magnesium Salicylate, Meclofenamae Sodium, Mefenamic Acid, Meloxicam, Methyl Butetisalicylate, Methyl Gentisate, Methyl Salicylate, Metiazinic Acid, Metifenazone, Mofebutazone, Mofezolac, Morazone Hydrochloride, Morniflurnate, Morpholine Salicylate, Nabumetone, Naproxen (Naproxen Sodium), Nifenazone, Niflumic Acid, Nimesulide, Oxametacin, Oxaprozin, Oxindanac, Oxyphenbutazone, Parsalmide, Phenybutazone, Phenyramidol Hydrochloride, Picenadol Hydrochloride, Picolamine Salicylate, Piketoprofen, Pirazolac, Piroxicam, Pirprofen, Pranoprofen, Pranosal, Proglumetacin Maleate, Proquazone, Protizinic Acid, Ramifenazone, Salacetamide, Salamidacetic Acid, Salicylamide, Salix, Salol, Salsalate, Sodium Aurothiomalate, Sodium Gentisate, Sodium Salicylate, Sodium Thiosalicylate, Sulindac, Superoxide Dismutase (Orgotein, Pegorgotein, Sudismase), Suprofen, Suxibuzone, Tenidap Sodium, Tenoxicam, Tetrydamine, Thurfyl Salicylate, Tiaprofenic, Tiaramide Hydrochloride, Tinoridine Hydrochloride, Tolfenamic Acid, Tometin Sodium, Triethanolamine Salicylate, Ufenamate, Zaltoprofen, Zidometacin and Zomepirac Sodium.

## VI. Pharmaceutical Compositions

The described derivative of triptolide can be formulated as pharmaceutical compositions and administered for any of the disorders described herein, including autoimmune and inflammatory disorders, in a host, including a human, in any of a variety of forms adapted to the chosen route of administration, including systemically, such as orally, or parenterally, by intravenous, intramuscular, topical, transdermal or subcutaneous routes.

The derivative of triptolide (or prodrug thereof) is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount of compound to treat autoimmune or anti-inflammatory disorders or the symptoms thereof in vivo without causing serious toxic effects in the patient treated.

A preferred dose of the derivatives of triptolide for all of the above-mentioned conditions will be in the range from about 1 to 75 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the prodrug can be calculated based on the weight of the parent derivative to be delivered.

The derivatives of triptolide are conveniently administered in units of any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. An oral dosage of 50-1000 mg is usually convenient, and more typically, 50-500 mg.

Ideally the derivatives of triptolide should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70  $\mu$ M, preferably about 1.0 to 10  $\mu$ M. This may be achieved, for example, by the intravenous injection of an appropriate concentration of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.

The concentration of the derivative of triptolide in the drug composition will depend on absorption, inactivation and excretion rates of the extract as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or

supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The derivative of triptolide may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

5 A preferred mode of administration of the derivative of triptolide is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

10 The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.

20 The derivative of triptolide can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. The derivatives of triptolide can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories, or other anti-autoimmune compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates

or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

In another embodiment, the derivatives of triptolide are prepared with carriers that will protect the derivatives against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.

Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl ethanolamine, stearyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

## VII. Synthesis of the Active Compounds


### *Formylation of a Substituted Phenol:*

The starting material for this process is a substituted phenol (A), which can be purchased or can be prepared by any known means to those of ordinary skill in the art. In one embodiment, formylation of the compound of formula (A) results in the formation of an aldehyde of formula (B). The said substituted phenol can be coupled with a

paraformaldehyde in a compatible solvent at a suitable temperature with the appropriate coupling reagent to yield the corresponding aldehyde. Possible coupling reagents are any reagents that promote coupling, including but not limited to  $\text{SnCl}_4$ ,  $\text{BF}_3$ ,  $\text{AlCl}_3$ ,  $\text{FeI}_3$ , or  $\text{ZnCl}_2$ , preferably  $\text{SnCl}_4$ .

The formylation reaction can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.

Any reaction solvent can be selected that can achieve the necessary temperature, can solubilize the reaction components and inert to the reagents. Nonlimiting examples are any aprotic solvent including, but not limited to the alkyl solvents, such as hexane and cyclohexane, toluene, acetone, ethyl acetate, dithianes, triethylamine (TEA), tetrahydrofuran (THF), dioxane, acetonitrile, dichloromethane, dichloroethane, diethyl ether, pyridine, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide or any combination thereof, though preferably TEA.




wherein  $\text{R}^1$ ,  $\text{R}^3$ , and  $\text{R}^4$  are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, a residue of a natural or synthetic amino acid, or carbohydrate or  $\text{XR}^7$  ( $\text{X} = \text{O}$ ,  $\text{NR}^8$  or  $\text{S}$ ).

### ***Reduction of Aldehyde:***

In another embodiment of the present invention, reducing the compound of formula B results in the formation of the alcohol of formula C using a reducing agent such

as NaBH<sub>4</sub>. The reduction reaction can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.

Any reaction solvent can be selected that can achieve the necessary temperature, can solubilize the reaction components and inert to the reagents. Nonlimiting examples are any aprotic solvent including, but not limited to the alkyl solvents, such as hexane and cyclohexane, toluene, acetone, ethyl acetate, dithianes, triethylamine (TEA), tetrahydrofuran (THF), dioxane, acetonitrile, dichloromethane, dichloroethane, diethyl ether, pyridine, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide or any combination thereof, though preferably TEA.



wherein R<sup>1</sup>, R<sup>3</sup>, and R<sup>4</sup> are selected independently from the groups that include hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, carboxylic acid, amide, nitro, cyano, azide, phosphonyl, phosphinyl, phosphoryl, phosphine, carbamate, ester, alkcarbonyl, carbonyl, a residue of a natural or synthetic amino acid, or carbohydrate or XR<sup>7</sup> (X = O, NR<sup>8</sup> or S).


#### ***Coupling of a Substituted Phenol:***

Alternatively, the substituted phenol can be formed using a ketone. Again, the starting material for this process is a substituted phenol (A), which can be purchased or can be prepared by any known means to those of ordinary skill in the art. In one embodiment, the compound of formula (A), is optionally protected, with an appropriate protecting group, as taught by Greene *et al.* Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991. Coupling of this optionally protected alcohol with an appropriate ketone results in the direct formation of an alcohol of formula (C'). The said substituted phenol can be coupled with the ketone in a compatible solvent at a suitable

temperature with the appropriate base to yield the corresponding aldehyde. Possible coupling reagents are any reagents that promote coupling, including but not limited to lithiates, including, BuLi.

The formylation reaction can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.

Any reaction solvent can be selected that can achieve the necessary temperature, can solubilize the reaction components and inert to the reagents. Nonlimiting examples are any aprotic solvent including, but not limited to the alkyl solvents, such as hexane and cyclohexane, toluene, acetone, ethyl acetate, dithianes, triethylamine (TEA), tetrahydrofuran (THF), dioxane, acetonitrile, dichloromethane, dichloroethane, diethyl ether, pyridine, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide or any combination thereof, though preferably TEA.




### ***Formation of Epoxides:***

In yet a further embodiment of the present invention, the epoxidation of the compounds of formula (C) or (C') yields compound (D). In another embodiment of the present invention, the compound of formula (D) is subjected to further oxidation resulting in the compound of formula (E) and (F). The formation of the monoepoxide (D) results from oxidizing the alcohol of formula (C) with an oxidizing agent such as sodium periodate (NaIO<sub>4</sub>). Upon further oxidation of the monoepoxide (D) using oxidizing agents such as mCPBA give rise to the compound of formula (E) and (F). The oxidation reaction can be carried out at any temperature that achieves the desired result, i.e., that is


suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.

Any reaction solvent can be selected that can achieve the necessary temperature, can solubilize the reaction components and inert to the reagents. Nonlimiting examples are any aprotic solvent including, but not limited to the alkyl solvents, such as hexane and cyclohexane, toluene, acetone, ethyl acetate, dithianes, triethylamine (TEA), tetrahydrofuran (THF), dioxane, acetonitrile, dichloromethane, dichloroethane, diethyl ether, pyridine, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide or any combination thereof, though preferably TEA.




It is yet a further embodiment of the present invention to further oxidize the compounds of formula (E) or (F) to give the stereoselective compounds of formula (G) or (H) respectively. Treating the compounds of formula (E) or (F) with an oxidizing agent such as hydrogen peroxide/NaOH yield the triepoxide (G) or (H) respectively. The oxidation reaction can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.





It is also a further embodiment of the present invention to provide for the compound of formula (J). The monoepoxide compound of formula (D) can be further oxidized to give the diepoxide compound of formula (J) using oxidizing agents such as hydrogen peroxide/NaOH. The oxidation reaction can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature.



In another embodiment of the invention, the sulfur analogs are desired. Therefore, the sulfur analogs corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding sulfur containing starting material.


#### ***Formation of Cyclopropyls:***

In yet a further embodiment of the present invention, the cyclopropanation of the compounds of formula (C) or (C') yields compound (K). The formation of compound (K) results from eliminating the alcohol of formula (C) with an acid to form the alkene. The

alkene can be reacted with the appropriate carbene to form the cyclopropane (K). The appropriate carbene can be made by any means known in the art. In particular, the carbene can be made via  $\alpha$ -elimination. For example, dichlorocarbene can be made by treatment of chloroform with a base. Alternatively, the carbene can be made via the Simmons-Smith procedure with Zn-Cu, or Zn and Cu-X (wherein X is a halide), and in particular Zn and Cu-X in the presence of  $TiX_4$ . The carbene also can be made by the disintegration of certain types of double bonds, such as the photolysis of a ketene, the isoelectronic decomposition of diazoalkanes, and the decomposition of diazirines (which are isometric with diazoalkanes). Alternatively, ylides, such as  $R_2P=CR^7$ ,  $R_2S(O)-CR^7R^8$ , such as Trost's and Corey's sulfur ylides, or  $R(NR_2)S(O)-CR^7R^8$ , that mimic a carbene, or transition metal-carbene complexes, such as  $L_nM=CR^7R^8$ , wherein M is a metal and L is a ligand, and in particular, when M is Fe, may also be used to form the desired cyclopropane.

Regardless, the coupling reaction with the carbene can be carried out at any temperature that achieves the desired result, i.e., that is suitable for the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products. The preferred temperature is room temperature. In the same way, any of the carbon-carbon pi bonds in compound (C) or (C') can be reacted with the appropriate carbene to form the desired cyclopropane.


Any reaction solvent can be selected that can achieve the necessary temperature, can solubilize the reaction components and inert to the reagents. Nonlimiting examples are any aprotic solvent including, but not limited to the alkyl solvents, such as hexane and cyclohexane, toluene, acetone, ethyl acetate, dithianes, triethylamine (TEA), tetrahydrofuran (THF), dioxane, acetonitrile, dichloromethane, dichloroethane, diethyl ether, pyridine, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide or any combination thereof, though preferably TEA.



### Example 1


#### *Synthesis of substituted benzyl alcohols.*

To a magnetically stirred solution of the phenol (20 mmol) in toluene (10 mL), triethylamine (8 mmol) was added followed by SnCl<sub>4</sub> (2 mmol). After stirring for 0.5 h at room temperature, paraformaldehyde (40 mmol) was added and the slurry heated to 95°C for 16 h. The reaction mixture was cooled and poured into water (40 mL) and acidified to pH 2 with 1 N HCl. The aqueous layer was extracted with diethyl ether (3 x 60 mL). The combined organics were washed with brine, dried (sodium sulphate) and concentrated under vacuo. The crude product (B) was subjected to reduction with NaBH<sub>4</sub> (1.5 equivalents) in MeOH at 0°C. After stirring the reaction for 1 h, the reaction mixture was quenched with a saturated solution of ammonium chloride and acidified to pH 4 with 1 N HCl. MeOH was removed under vacuum and the aqueous layer extracted with ethyl acetate (2 x 50 mL). The combined organics were washed with brine, dried (sodium sulfate) and concentrated under vacuo. Flash chromatography using 1:4::ethyl acetate: hexanes yielded the desired product C in moderate yield over 2 steps (35-60%).




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.9 (br s, 1H), 7.06 (d, 1H,  $J = 7.8$  Hz), 6.7 (d, 1H,  $J = 7.8$  Hz), 4.94 (s, 2H), 3.3 (m, 1H), 2.24 (s, 3H), 1.24 (d, 6H,  $J = 6.9$  Hz).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 154.02, 133.90, 132.89, 125.62, 122.19, 121.90, 61.38, 26.75, 22.98, 19.40.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.92 (br s, 1H), 7.04 (d, 1H,  $J = 7.8$  Hz), 4.93 (s, 2H), 2.9 (m, 1H), 2.23 (s, 3H), 1.8 (m, 6H), 1.36 (m, 4H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 153.91, 133.11, 132.85, 126.12, 122.20, 121.90, 61.33, 36.88, 33.5, 27.35, 26.69, 19.39.



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 8.1 (br s, 1H), 7.15 (d, 1H,  $J = 7.8$  Hz), 6.67 (d, 1H,  $J = 7.8$  Hz), 4.92 (s, 2H), 2.25 (s, 3H), 1.43 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 156.17, 135.36, 133.54, 126.43, 123.06, 121.55, 61.26, 34.69, 29.84, 19.26.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.48 (s, 1H), 7.02 (s, 1H), 6.68 (s, 1H), 4.78 (s, 2H), 2.22 (s, 3H), 1.38 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 153.15, 137.19, 128.41, 127.79, 126.49, 124.80, 65.20, 34.76, 29.81, 20.85

## Example 2


### *Formation of monoepoxide using sodium periodate:*

To a magnetically stirred solution of **C** (2 mmol) in MeOH (12 mL), a solution of  $\text{NaIO}_4$  (2.2 mmol) in 3 mL water was added dropwise at  $0^\circ\text{C}$ . After one minute of stirring a precipitate began to appear. After stirring for another 20 minutes the precipitate was filtered and washed with  $\text{CHCl}_3$ . Water was added and the aqueous layer was extracted with chloroform. The combined organics were washed with brine, dried (sodium sulfate) and concentrated under vacuo. Purification by flash chromatography using 1:7::ethyl acetate: hexanes yielded the desired product (**D**, 80%).



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.87 (d, 1H,  $J = 6.6$  Hz), 6.3 (m, 1H), 3.22 (d, 1H,  $J = 8.1$  Hz), 3.15 (d, 1H,  $J = 8.1$  Hz), 2.9 (m, 1H), 1.79 (d, 3H,  $J = 1.5$  Hz), 1.08 (d, 3H,  $J = 2.1$  Hz), 1.05 (d, 3H,  $J = 2.1$  Hz).


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 195.31, 144.45, 141.75, 135.62, 124.02, 59.27, 58.81, 26.45, 22.14, 21.88, 16.42.



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.8 (m, 1H), 6.23 (m, 1H), 3.14 (m, 1H), 3.05 (m, 1H), 2.52 (m, 1H), 1.65 (m, 8H), 1.27 (m, 2H), 1.1 (m, 3H)

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 195.41, 144.30, 140.89, 136.13, 124.10, 59.12, 58.70, 35.79, 32.56, 32.31, 26.68, 26.59, 26.28, 16.15.


5



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.94 (d, 1H,  $J = 6.3$  Hz), 6.27 (d, 1H,  $J = 6.3$  Hz), 3.14 (AB quartet, 2H,  $J = 8.1$  Hz), 1.79 (s, 3H), 1.21 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 195.07, 145.18, 143.06, 136.44, 123.98, 59.85, 58.44, 34.34, 29.14, 16.19.

10



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.79 (d, 1H,  $J = 2.1$  Hz), 5.68 (d, 1H,  $J = 2.1$  Hz), 3.23 (d, 1H,  $J = 8.1$  Hz), 3.01 (d, 1H,  $J = 8.1$  Hz), 1.98 (s, 3H), 1.20 (s, 9H).


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 194.42, 144.74, 140.25, 135.79, 130.94, 58.92, 57.26, 34.55, 29.23, 22.00.

15

### Example 3


#### *Formation of diepoxides from the monoepoxides using mCPBA:*

To a magnetically stirred solution of **D** (1 mmol) in methylene chloride (10 mL), mCPBA was added and the reaction mixture stirred for 14 h. The mixture was diluted with methylene chloride and washed twice with saturated sodium carbonate. The combined organics were washed with brine, dried (sodium sulfate) and concentrated under vacuo. Purification by flash chromatography using 1:7::ethyl acetate:hexanes yielded 2 products that were separated. Stereochemical assignments were made by comparison with literature data. Typically the higher  $R_F$  spot was assigned the stereochemistry **F** and the lower  $R_F$  spot was assigned the stereochemistry **E**. The combined yield for the reaction was typically 70%.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.95 (d, 1H,  $J = 4.5$  Hz), 3.46 (d, 1H,  $J = 4.5$  Hz), 3.42 (d, 1H,  $J = 6.6$  Hz), 3.1 (d, 1H,  $J = 6.6$  Hz), 2.85 (m, 1H), 1.31 (s, 3H), 1.04 (d, 3H,  $J = 5.1$  Hz), 1.02 (d, 3H,  $J = 5.1$  Hz).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 190.71, 149.44, 136.89, 61.39, 55.66, 54.43, 50.11, 27.40, 21.67, 21.64, 16.16.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.9 (d, 1H,  $J = 4.5$  Hz), 3.51 (d, 1H,  $J = 4.8$  Hz), 2.96 (d, 1H,  $J = 6.3$  Hz), 2.87 (d, 1H,  $J = 6.3$  Hz), 2.79 (m, 1H), 1.32 (s, 3H), 1.06 (d, 3H,  $J = 6.9$  Hz), 0.97 (d, 3H,  $J = 6.9$  Hz).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 191.06, 150.00, 136.40, 59.62, 57.92, 54.55, 52.66, 27.51, 21.69, 21.55, 15.63.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.89 (d, 1H,  $J = 3.3$  Hz), 3.44 (d, 1H,  $J = 3.3$  Hz), 3.38 (d, 1H,  $J = 4.8$  Hz), 3.09 (d, 1H,  $J = 4.8$  Hz), 2.49 (m, 1H), 1.71 (m, 5H), 1.3 (s, 3H), 1.33 – 1.03 (m, 5H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 190.89, 148.72, 137.42, 61.3, 55.59, 54.42, 50.04, 36.85, 32.25, 26.58, 26.56, 26.26, 16.02.



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.83 (d, 1H,  $J = 3.6$  Hz), 3.5 (d, 1H,  $J = 3.6$  Hz), 2.94 (m, 1H), 2.82 (m, 1H), 2.45 (br t, 1H), 1.73 – 1.52 (m, 5H), 1.13 (s, 3H), 1.26 – 0.96 (m, 5H).


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 191.27, 149.21, 136.87, 59.58, 57.76, 54.52, 52.51, 36.85, 32.31, 31.99, 26.50, 26.41, 26.14, 15.39.



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.92 (d, 1H,  $J = 3.3$  Hz), 3.49 (d, 1H,  $J = 3.3$  Hz), 2.89 (d, 1H,  $J = 4.2$  Hz), 2.79 (d, 1H,  $J = 4.2$  Hz), 1.31 (s, 3H), 1.14 (s, 9H).


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 191.21, 151.52, 136.77, 60.76, 57.35, 54.44, 51.60, 35.05, 28.90, 14.97.





$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.78 (s, 1H), 3.44 (d, 1H,  $J = 6.6$  Hz), 3.21 (s, 1H), 3.03 (d, 1H,  $J = 6.6$  Hz), 1.57 (s, 3H), 1.12 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 190.07, 149.46, 142.55, 63.23, 54.31, 54.00, 51.34, 35.16, 29.05, 21.07.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.72 (s, 1H), 3.13 (s, 1H), 2.89 (s, 2H), 1.57 (s, 3H), 1.09 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 190.07, 150.01, 142.08, 60.59, 58.08, 54.85, 52.96, 35.03, 28.98, 21.11.

#### Example 4


***Oxidation of monoepoxides and diepoxides to diepoxides and triepoxides respectively using hydrogen peroxide:***

To a magnetically stirred solution of **D** or **F** or **E** (1 mmol) in MeOH (10 mL) at room temperature, 1 N NaOH (0.47 mL) was added followed immediately by the addition of 30 %  $\text{H}_2\text{O}_2$  (1.5 mmol). After 40 minutes of stirring at room temperature, water was added (40 mL) and the aqueous layer extracted with ethyl acetate (3 x 60 mL). The combined organics were washed with brine, dried (sodium sulfate) and concentrated under vacuo. Flash chromatography using 1;6::ethyl acetate:hexanes yielded the desired product **J**, **H** or **G** respectively in moderate yield (60%).




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.81 (d, 1H,  $J = 2.4$  Hz), 3.62 (d, 1H,  $J = 2.4$  Hz), 3.38 (d, 1H,  $J = 5.2$  Hz), 2.9 (d, 1H,  $J = 5.2$  Hz), 2.39 (m, 1H), 1.23 (s, 3H), 0.96 (d, 3H,  $J = 6.8$  Hz), 0.87 (d, 3H,  $J = 6.8$  Hz).

5  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 198.03, 66.15, 59.2, 58.72, 58.5, 56.59, 47.43, 26.02, 18.24, 16.37, 15.62.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.85 (d, 1H,  $J = 2.8$  Hz), 3.67 (d, 1H,  $J = 2.8$  Hz), 2.95 (d, 1H,  $J = 5.2$  Hz), 2.74 (d, 1H,  $J = 5.2$  Hz), 2.4 (m, 1H), 1.23 (s, 3H), 0.96 (d, 3H,  $J = 6.8$  Hz), 0.87 (d, 3H,  $J = 6.8$  Hz)

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 197.67, 67.22, 60.32, 59.53, 58.43, 50.69, 25.75, 18.11, 16.65, 14.73.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.84 (d, 1H,  $J = 2.8$  Hz), 3.61 (d, 1H,  $J = 2.8$  Hz), 3.36 (d, 1H,  $J = 4.2$  Hz), 2.98 (d, 1H,  $J = 4.2$  Hz), 2.12 (m, 1H), 1.74 – 1.58 (m, 5H), 1.23 (s, 3H), 1.28 – 0.87 (m, 5H).

15  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 198.04, 65.85, 59.27, 58.78, 58.44, 56.68, 47.42, 35.07, 28.53, 26.49, 26.24, 26.00, 25.91, 15.57.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.88 (d, 1H,  $J = 2.8$  Hz), 3.66 (d, 1H,  $J = 2.8$  Hz), 2.94 (d, 1H,  $J = 5.2$  Hz), 2.72 (d, 1H,  $J = 5.2$  Hz), 2.15 (m, 1H), 1.73 – 1.63 (m, 5H), 1.22 (s, 3H), 1.28 – 0.89 (m, 5H).

5  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 197.66, 66.93, 60.42, 60.31, 59.48, 58.48, 50.59, 34.64, 28.34, 26.74, 26.16, 25.91, 14.66.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 6.08 (m, 1H), 3.73 (d, 1H,  $J = 3$  Hz), 2.94 (s, 2H), 1.61 (s, 3H), 1.09 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 200.05, 141.71, 123.21, 64.42, 60.21, 56.4, 52.92, 32.10, 25.76, 15.67.




$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.92 (d, 1H,  $J = 3$  Hz), 3.62 (d, 1H,  $J = 3$  Hz), 2.89 (d, 1H,  $J = 5.1$  Hz), 2.67 (d, 1H,  $J = 5.1$  Hz), 1.19 (s, 3H), 1.00 (s, 9H).

15  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 196.86, 68.49, 61.05, 60.19, 59.46, 58.12, 50.22, 32.31, 25.65, 14.47



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.72 (s, 1H), 2.95 (d, 1H,  $J = 5.4$  Hz), 2.81 (d, 1H,  $J = 5.4$  Hz), 1.66 (s, 3H), 1.01 (s, 9H)

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 196.56, 68.30, 64.58, 61.63, 59.03, 58.30, 51.04, 32.43, 25.79, 20.13.



$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 3.72, (d, 1H,  $J = 1.5$  Hz), 3.41 (d, 1H,  $J = 5.7$  Hz), 2.8 (m, 2H), 1.64 (s, 3H), 1.01 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 196.94, 67.45, 63.68, 60.50, 58.29, 54.5, 50.79, 32.45, 25.92, 19.97.